Document:

2010 Employee Stock Purchase Plan

 Exhibit 10.6 
 ZOGENIX, INC. 
 2010 EMPLOYEE STOCK PURCHASE PLAN 

ARTICLE I 

PURPOSE 

The purposes of this Zogenix, Inc. 2010 Employee Stock Purchase Plan (the “Plan”) are to assist Eligible
Employees of Zogenix, Inc., a Delaware corporation (the “Company”) and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee
stock purchase plan” within the meaning of Section 423(b) of the Code, and to help Eligible Employees provide for their future security and to encourage them to remain in the employment of the Company and its Designated Subsidiaries.

 All numbers of shares of Stock set forth in the Plan give effect to the reverse stock split to be implemented by the Company
in connection with its initial public offering. 
 ARTICLE II 

DEFINITIONS AND CONSTRUCTION 
 Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the
context so indicates. 
 2.1 “Administrator” shall mean the entity that conducts the general
administration of the Plan as provided herein. The term “Administrator” shall refer to the Committee unless the Board has assumed the authority for administration of the Plan generally as provided in Article 3. 

2.2 “Board” shall mean the Board of Directors of the Company. 

2.3 “Change in Control” shall mean and include each of the following: 

(a) A transaction or series of transactions (other than an offering of Stock to the general public through a registration statement filed
with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its
Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company)
directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding
immediately after such acquisition; or 
 (b) During any period of two consecutive years, individuals who, at the beginning of
such period, constitute the Board together with any new director(s) (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in clause (a) above or clause
(c) below) whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two year
period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or 

 (c) The consummation by the Company (whether directly involving the Company or indirectly
involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single
transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: 
 (i) Which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting
securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business
of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the
transaction, and 
 (ii) After which no person or group beneficially owns voting securities representing 50% or more of the
combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of combined voting power of the Successor Entity solely as a
result of the voting power held in the Company prior to the consummation of the transaction. 
 The Administrator shall have
full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and
any incidental matters relating thereto. 
 2.4 “Code” shall mean the Internal Revenue Code of 1986, as
amended from time to time, and the regulations issued thereunder. 
 2.5 “Committee” shall mean the
committee of the Board described in Article 3. 
 2.6 “Company” shall mean Zogenix, Inc., a Delaware
corporation. 
 2.7 “Compensation” of an Eligible Employee shall mean the gross base compensation
received by such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, excluding overtime payments, sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special
payments. 
 2.8 “Designated Subsidiary” shall mean any Subsidiary designated by the Administrator in
accordance with Section 3.3(b). 
 2.9 “Eligible Employee” shall mean an Employee of the Company or
a Designated Subsidiary: (a) who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of Stock or other
stock of the Company, a Parent or a Subsidiary (as determined under Section 423(b)(3) of the Code); (b) whose customary employment is for more than twenty hours per week; and (c) whose customary employment is for more than five months
in any calendar year; provided, however, that the Administrator may provide in an Offering Document that (i) Employees who are highly compensated employees within the meaning of Section 423(b)(4)(D) of the Code, and/or
(ii) Employees who have not met a service requirement designated by the Administrator pursuant to Section 423(b)(4)(A) of the Code (which service requirement may not exceed two years), shall not be eligible to participate in an Offering
Period. For purposes of clause (a) above, the rules of Section 424(d) of the Code with regard to the 

  
 2 

 
attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock which an Employee may purchase under outstanding options shall be treated as stock owned
by the Employee. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or a Designated Subsidiary and meeting the
requirements of Treasury Regulation Section 1.421-7(h)(2). 
 In addition, “Eligible Employee”
shall not include any Employee of a Designated Subsidiary who is a citizen or resident of a foreign jurisdiction if the grant of a right to purchase Stock under the Plan to such Employee would be prohibited under the laws of such foreign
jurisdiction or the grant of an option to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of Section 423 of the Code, as determined by the Administrator in its sole
discretion. 
 2.10 “Employee” shall mean any officer or other employee (as defined in accordance with
Section 3401(c) of the Code) of the Company or any Designated Subsidiary. 
 2.11 “Enrollment Date”
shall mean the first day of each Offering Period. 
 2.12 “Exchange Act” shall mean the Securities
Exchange Act of 1934, as amended from time to time. 
 2.13 “Fair Market Value” means, as of any given
date, the fair market value of a share of Stock on the date determined as follows: 
 (a) If the Stock is listed on any
(i) established securities exchange (such as the New York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) national market system or (iii) automated quotation system on which the Stock is listed,
quoted or traded, its Fair Market Value shall be the closing sales price for a share of Stock as quoted on such exchange or system for such date or, if there is no closing sales price for a share of Stock on the date in question, the closing sales
price for a share of Stock on the last preceding date for which such quotation exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 

(b) If the Stock is not listed on an established securities exchange, national market system or automated quotation system, but the Stock
is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a share of Stock on such date, the high bid and
low asked prices for a share of Stock on the last preceding date for which such information exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or 

(c) If the Stock is neither listed on an established securities exchange, national market system or automated quotation system nor
regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith, as of any given date, the fair market value of a share of Stock on the date determined by such methods or procedures
as may be established from time to time by the Administrator. 
 2.14 “Offering Document” shall have the
meaning given to such term in Section 5.1. 
 2.15 “Offering Period” shall mean each Offering
Period designated by the Administrator in the applicable Offering Document pursuant to Section 5.1. 

  
 3 

 2.16 “Parent” shall mean any corporation, other than the Company, in
an unbroken chain of corporations ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of
the other corporations in such chain. 
 2.17 “Participant” shall mean any Eligible Employee who has
executed a subscription agreement and been granted rights to purchase Stock pursuant to the Plan. 
 2.18
“Plan” shall mean this Zogenix, Inc. 2010 Employee Stock Purchase Plan, as it may be amended from time to time. 
 2.19 “Purchase Date” shall mean the last day of each Purchase Period. 
 2.20 “Purchase Period” shall mean each Purchase Period designated by the Administrator in the applicable Offering Document pursuant to Section 5.1. A new Purchase Period will
begin on the day immediately following a Purchase Date. 
 2.21 “Purchase Price” shall mean the purchase
price designated by the Administrator in the applicable Offering Document (which purchase price shall not be less than 85% of the Fair Market Value of a share of Stock on the Enrollment Date or on the Purchase Date, whichever is lower);
provided, however, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering Periods covered by such Offering Document shall be 85% of the Fair
Market Value of a share of Stock on the Enrollment Date or on the Purchase Date, whichever is lower; provided, further, that the Purchase Price may be adjusted by the Administrator pursuant to Article 9; provided,
further, that the Purchase Price shall not be less than the par value of a share of Stock. 
 2.22 “Securities
Act” shall mean the Securities Act of 1933, as amended from time to time. 
 2.23 “Stock”
shall mean the common stock of the Company and such other securities of the Company that may be substituted for Stock pursuant to Article 9. 
 2.24 “Subsidiary” shall mean any corporation, other than the Company, in an unbroken chain of corporations beginning with the Company if, at the time of the determination, each of
the corporations other than the last corporation in an unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. 

ARTICLE III 
 ADMINISTRATION 
 3.1 Administrator. The Administrator of the Plan
shall be the Compensation Committee of the Board (or another committee or a subcommittee of the Board to which the Board delegates administration of the Plan) (such committee, the “Committee”), which Committee shall consist
solely of two or more members of the Board each of whom is a “non-employee director” within the meaning of Rule 16b-3 which has been adopted by the Securities and Exchange Commission under the Exchange Act and which Committee is otherwise
constituted to comply with applicable law. The Board may abolish the Committee at any time and vest in the Board the administration of the Plan. 

  
 4 

 3.2 Action by the Administrator. A majority of the Administrator shall constitute a
quorum. The acts of a majority of the members present at any meeting at which a quorum is present, and, subject to applicable law and the Bylaws of the Company, acts approved in writing by a majority of the Administrator in lieu of a meeting, shall
be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Designated
Subsidiary, the Company’s independent certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan. 

3.3 Authority of Administrator. The Administrator shall have the power, subject to, and within the limitations of, the express
provisions of the Plan: 
 (a) To determine when and how rights to purchase Stock shall be granted and the provisions of each
offering of such rights (which need not be identical). 
 (b) To designate from time to time which Subsidiaries of the Company
shall be Designated Subsidiaries, which designation may be made without the approval of the shareholders of the Company. 
 (c)
To construe and interpret the Plan and rights granted under it, and to establish, amend and revoke rules and regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in
the Plan, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective. 
 (d) To amend
the Plan as provided in Article 10. 
 (e) Generally, to exercise such powers and to perform such acts as the Administrator
deems necessary or expedient to promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated as an “employee stock purchase plan” within the meaning of Section 423 of the Code.

 3.4 Decisions Binding. The Administrator’s interpretation of the Plan, any rights granted pursuant to the Plan,
any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. 
 ARTICLE IV 
 SHARES SUBJECT TO THE PLAN 

4.1 Number of Shares. Subject to Article 9, the aggregate number of shares of Stock which may be issued pursuant to rights granted
under the Plan shall be 500,000 shares. In addition to the foregoing, subject to Article 9, commencing on the first January 1 following the Effective Date, and on each January 1 thereafter during the term of the Plan, the number of shares
of Stock which shall be made available for sale under the Plan shall be increased by that number of shares of Stock equal to the least of (a) 1% of the Company’s outstanding shares on such date, (b) 250,000 shares, or (c) a
lesser amount determined by the Board. Accordingly, the number of shares of Stock which shall be available for sale under the Plan shall be subject to increase under the preceding sentence only on the first January 1 following the Effective
Date and on each subsequent January 1 through and including January 1, 2020. If any right granted under the Plan shall for any reason terminate without having been exercised, the Stock not purchased under such right shall again become
available for the Plan. Notwithstanding anything in this Section 4.1 to the contrary, the number of shares of Stock that may be issued or transferred pursuant to rights granted under the Plan shall not exceed an aggregate of 3,000,000 shares,
subject to Article 9. 

  
 5 

 4.2 Stock Distributed. Any Stock distributed pursuant to the Plan may consist, in
whole or in part, of authorized and unissued Stock, treasury stock or Stock purchased on the open market. 
 ARTICLE V

 OFFERING PERIODS; OFFERING DOCUMENTS; PURCHASE DATES 

5.1 Offering Periods. The Administrator may from time to time grant or provide for the grant of rights to purchase Stock of the
Company under the Plan to Eligible Employees during one or more periods (each, an “Offering Period”) selected by the Administrator commencing on such dates (each, an “Enrollment Date”) selected by the
Administrator. The terms and conditions applicable to each Offering Period shall be set forth in an “Offering Document” adopted by the Administrator, which Offering Document shall be in such form and shall contain such terms
and conditions as the Administrator shall deem appropriate and shall be incorporated by reference into and made part of the Plan and shall be attached hereto as part of the Plan. The Administrator shall establish in each Offering Document one or
more dates during an Offering Period (the “Purchase Date(s)”) on which rights granted under the Plan shall be exercised and purchases of Stock carried out during such Offering Period in accordance with such Offering Document
and the Plan. The provisions of separate Offering Periods under the Plan need not be identical. 
 5.2 Offering
Documents. Each Offering Document with respect to an Offering Period shall specify (through incorporation of the provisions of this Plan by reference or otherwise): 
 (a) the length of the Offering Period, which period shall not exceed twenty-seven months; 
 (b) the Enrollment Date for such Offering Period; 
 (c) the Purchase Date(s)
during such Offering Period; 
 (d) the maximum number of shares that may be purchased by any Eligible Employee during such
Offering Period, which, in the absence of a contrary designation by the Administrator, shall be 20,000 shares; 
 (e) in
connection with each Offering Period that contains more than one Purchase Date, the maximum aggregate number of shares which may be purchased by any Eligible Employee on any given Purchase Date during the Offering Period, which, in the absence of a
contrary designation by the Administrator, shall be 20,000 shares; and 
 (f) such other provisions as the Administrator
determines are appropriate, subject to the Plan. 
 ARTICLE VI 

PARTICIPATION 
 6.1 Eligibility. Any Eligible Employee who shall be employed by the Company or a Designated Subsidiary on the day immediately preceding a given Enrollment Date for an Offering Period shall be
eligible to participate in the Plan during such Offering Period, subject to the requirements of this Article 6 and the limitations imposed by Section 423(b) of the Code. 

  
 6 

 6.2 Enrollment in Plan. Except as otherwise set forth in an Offering Document, an
Eligible Employee may become a Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document), in
such form as the Administrator provides. Each such agreement shall designate a whole percentage of such Eligible Employee’s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each payday
during the Offering Period as payroll deductions under the Plan. An Eligible Employee may designate any whole percentage of Compensation which is not less than 1% and not more than the maximum percentage specified by the Administrator in the
applicable Offering Document (which percentage shall be 20% in the absence of any such designation) as payroll deductions. The payroll deductions made for each Participant shall be credited to an account for such Participant under the Plan and shall
be deposited with the general funds of the Company. A Participant may reduce (but not increase) the percentage of Compensation designated in his or her subscription agreement, subject to the limits of this Section 6.2 at any time during an
Offering Period; provided, however, that the Administrator may limit the number of changes a Participant may make to his or her payroll deduction elections during each Offering Period and/or Purchase Period in the applicable Offering
Document (and in the absence of any specific designation by the Administrator, a Participant shall be allowed two changes to his or her payroll deduction elections during each Offering Period). Any such change to payroll deductions shall be
effective with the first full payroll period following five business days after the Company’s receipt of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering
Document). Except as otherwise set forth in an Offering Document, a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period. 

6.3 Payroll Deductions. Except as otherwise provided in the applicable Offering Document, payroll deductions for a Participant
shall commence on the first payroll following the Enrollment Date and shall end on the last payroll in the Offering Period to which his or her authorization is applicable, unless sooner terminated by the Participant as provided in Article 9.

 6.4 Effect of Enrollment. A Participant’s completion of a subscription agreement will enroll such Participant in
the Plan for each successive Purchase Period and each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation under the Plan as provided in Article 8
or otherwise becomes ineligible to participate in the Plan. 
 6.5 Limitation on Purchase of Stock. An Eligible Employee
may be granted rights under the Plan only if such rights, together with any other rights granted to such Eligible Employee under “employee stock purchase plans” of the Company, any Parent or any Subsidiary, as specified by
Section 423(b)(8) of the Code, do not permit such employee’s rights to purchase stock of the Company or any Parent or Subsidiary to accrue at a rate which exceeds $25,000 of fair market value of such stock (determined as of the first day
of the Offering Period during which such rights are granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section 423(b)(8) of the Code. 

  
 7 

 6.6 Decrease or Suspension of Payroll Deductions. Notwithstanding the foregoing, to
the extent necessary to comply with Section 423(b)(8) of the Code and Section 6.5 or the other limitations set forth in this Plan, a Participant’s payroll deductions may be suspended by the Administrator at any time during an Offering
Period. The balance of the amount credited to the account of each Participant which has not been applied to the purchase of shares of Stock by reason of Section 423(b)(8) of the Code, Section 6.5 or the other limitations set forth in this
Plan shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. 
 6.7
Foreign Employees. In order to facilitate participation in the Plan, the Administrator may provide for such special terms applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed by a Designated
Subsidiary outside of the United States, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Such special terms may not be more favorable than the terms of rights granted under
the Plan to Eligible Employees who are residents of the United States. Moreover, the Administrator may approve such supplements to, or amendments, restatements or alternative versions of, this Plan as it may consider necessary or appropriate for
such purposes without thereby affecting the terms of this Plan as in effect for any other purpose. No such special terms, supplements, amendments or restatements shall include any provisions that are inconsistent with the terms of this Plan as then
in effect unless this Plan could have been amended to eliminate such inconsistency without further approval by the shareholders of the Company. 
 ARTICLE VII 
 GRANT AND EXERCISE OF RIGHTS 

7.1 Grant of Rights. On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period
shall be granted a right to purchase the maximum number of shares of Stock specified under Section 5.2(d), subject to the limits in Section 6.5, and shall have the right to buy, on each Purchase Date during such Offering Period (at the
applicable Purchase Price), such number of shares of the Company’s Stock as is determined by dividing (a) such Participant’s payroll deductions accumulated prior to such Purchase Date and retained in the Participant’s account as
of the Purchase Date, by (b) the applicable Purchase Price. The right shall expire on the last day of the Offering Period. 

7.2 Exercise of Rights. On each Purchase Date, each Participant’s accumulated payroll deductions and any other additional
payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole shares of Stock of the Company, up to the maximum number of shares permitted pursuant to the terms of the Plan and the applicable
Offering Document, at the Purchase Price. No fractional shares shall be issued upon the exercise of rights granted under the Plan, unless the Offering Document specifically provides otherwise. Any cash in lieu of fractional shares of Stock remaining
after the purchase of whole shares of Stock upon exercise of a purchase right will be credited to a Participant’s account and carried forward and applied toward the purchase of whole shares of Stock for the next following Offering Period.
Shares issued pursuant to the Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures. 

7.3 Pro Rata Allocation of Shares. If the Administrator determines that, on a given Purchase Date, the number of shares of Stock
with respect to which rights are to be exercised may exceed (a) the number of shares of Stock that were available for issuance under the Plan on the Enrollment Date of the applicable Offering Period, or (b) the number of shares of Stock
available for issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a 

  
 8 

 
pro rata allocation of the shares of Stock available for purchase on such Enrollment Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine
in its sole discretion to be equitable among all Participants for whom rights to purchase Stock are to be exercised pursuant to this Article 7 on such Purchase Date, and shall either (a) continue all Offering Periods then in effect, or
(b) terminate any or all Offering Periods then in effect pursuant to Article 10. The Company may make pro rata allocation of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence,
notwithstanding any authorization of additional shares for issuance under the Plan by the Company’s shareholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each Participant which has not been
applied to the purchase of shares of Stock shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. 
 7.4 Withholding. At the time a Participant’s rights under the Plan are exercised, in whole or in part, or at the time some or all of the Stock issued under the Plan is disposed of, the
Participant must make adequate provision for the Company’s federal, state, or other tax withholding obligations, if any, which arise upon the exercise of the right or the disposition of the Stock. At any time, the Company may, but shall not be
obligated to, withhold from the Participant’s compensation the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available to the Company any tax deductions or benefits
attributable to sale or early disposition of Stock by the Participant. 
 7.5 Conditions to Issuance of Stock. The
Company shall not be required to issue or deliver any certificate or certificates for, or make any book entries evidencing, shares of Stock purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions:

 (a) The admission of such shares to listing on all stock exchanges, if any, on which the Stock is then listed; and

 (b) The completion of any registration or other qualification of such shares under any state or federal law or under the
rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable; and 

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its
absolute discretion, determine to be necessary or advisable; and 
 (d) The payment to the Company of all amounts which it is
required to withhold under federal, state or local law upon exercise of the rights, if any; and 
 (e) The lapse of such
reasonable period of time following the exercise of the rights as the Administrator may from time to time establish for reasons of administrative convenience. 
 ARTICLE VIII 
 WITHDRAWAL; TERMINATION OF EMPLOYMENT OR ELIGIBILITY

 8.1 Withdrawal. A Participant may withdraw all but not less than all of the payroll deductions credited to his or
her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Administrator no later than 

  
 9 

 
one (1) week prior to the end of the Offering Period. All of the Participant’s payroll deductions credited to his or her account during an Offering Period shall be paid to such
Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant’s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of shares shall be
made for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions shall not resume at the beginning of the next Offering Period unless the Participant delivers to the Company a new subscription agreement.

 8.2 Future Participation. A Participant’s withdrawal from an Offering Period shall not have any effect upon his
or her eligibility to participate in any similar plan which may hereafter be adopted by the Company or a Designated Subsidiary or in subsequent Offering Periods which commence after the termination of the Offering Period from which the Participant
withdraws. 
 8.3 Cessation of Eligibility. Upon a Participant’s ceasing to be an Eligible Employee for any reason,
he or she shall be deemed to have elected to withdraw from the Plan pursuant to this Article 8 and the payroll deductions credited to such Participant’s account during the Offering Period shall be paid to such Participant or, in the case of his
or her death, to the person or persons entitled thereto under Section 12.4, as soon as reasonably practicable, and such Participant’s rights for the Offering Period shall be automatically terminated. 

ARTICLE IX 

ADJUSTMENTS UPON CHANGES IN STOCK 
 9.1 Changes in Capitalization. Subject to Section 9.3, in the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation, spin-off, recapitalization,
distribution of Company assets to shareholders (other than normal cash dividends), or any other corporate event affecting the Stock or the share price of the Stock, the Administrator may make such proportionate adjustments, if any, as the
Administrator in its discretion may deem appropriate to reflect such change with respect to (a) the aggregate number and type of shares of Stock (or other securities or property) that may be issued under the Plan (including, but not limited to,
adjustments of the limitations in Section 4.1 and the limitations established in each Offering Document pursuant to Section 5.2 on the maximum number of shares of Stock that may be purchased); (b) the class(es) and number of shares
and price per share of Stock subject to outstanding rights; and (c) the Purchase Price with respect to any outstanding rights. 
 9.2 Other Adjustments. Subject to Section 9.3, in the event of any transaction or event described in Section 9.1 or any unusual or nonrecurring transactions or events affecting the
Company, any affiliate of the Company, or the financial statements of the Company or any affiliate (including without limitation any Change in Control), or of changes in applicable laws, regulations or accounting principles, and whenever the
Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan, to facilitate
such transactions or events or to give effect to such changes in laws, regulations or principles, the Administrator, in its sole discretion and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the
following actions: 

  
 10 

  
 (a) To provide for
either (i) termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii) the replacement
of such outstanding right with other rights or property selected by the Administrator in its sole discretion; 
 (b) To provide
that the outstanding rights under the Plan shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar rights covering the stock of the successor or survivor corporation, or a
parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices; and 
 (d) To make
adjustments in the number and type of shares of Stock (or other securities or property) subject to outstanding rights under the Plan and/or in the terms and conditions of outstanding rights and rights which may be granted in the future; 

(d) To provide that Participants’ accumulated payroll deductions may be used to purchase Stock prior to the next occurring Purchase
Date on such date as the Administrator determines in its sole discretion and the Participants’ rights under the ongoing Offering Period(s) terminated; and 
 (e) To provide that all outstanding rights shall terminate without being exercised. 
 9.3 No Adjustment Under Certain Circumstances. No adjustment or action described in this Article 9 or in any other provision of the Plan shall be authorized to the extent that such adjustment or
action would cause the Plan to fail to satisfy the requirements of Section 423 of the Code. 
 9.4 No Other Rights.
Except as expressly provided in the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of
any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Stock subject to an Award or the grant or exercise price of any
Award. 
 ARTICLE X 
 AMENDMENT, MODIFICATION AND TERMINATION 
 10.1 Amendment, Modification
and Termination. The Administrator may amend, suspend or terminate the Plan at any time and from time to time; provided, however, that approval by a vote of the holders of the outstanding shares of the Company’s capital stock
entitled to vote shall be required to amend the Plan to: (a) change the aggregate number or type of shares that may be sold pursuant to rights under the Plan under Section 4.1 (other than any adjustment as provided by Article 9);
(b) change the corporations or classes of corporations whose employees may be granted rights under the Plan; or (c) change the Plan in any manner that would cause the Plan to no longer be an “employee stock purchase plan” within
the meaning of Section 423(b) of the Code. 
 10.2 Rights Previously Granted. Except as provided in Article 9 or
this Article 10, no termination, amendment or modification may make any change in any right theretofore granted which adversely affects the rights of any Participant without the consent of such Participant, provided that an Offering Period
may be terminated, amended or modified by the Administrator if the Administrator determines that the termination of the Offering Period or the Plan is in the best interests of the Company and its shareholders. 

  
 11 

 10.3 Certain Changes to Plan. Without shareholder consent and without regard to
whether any Participant rights may be considered to have been adversely affected, to the extent permitted by Section 423 of the Code, the Administrator shall be entitled to change the Offering Periods, limit the frequency and/or number of
changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to
adjust for delays or mistakes in the Company’s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the
purchase of Stock for each Participant properly correspond with amounts withheld from the Participant’s Compensation, and establish such other limitations or procedures as the Administrator determines in its sole discretion advisable which are
consistent with the Plan. 
 ARTICLE XI 
 TERM OF PLAN 
 The Plan shall be effective on the business day immediately
preceding the date on which the Registration Statement filed with respect to the Plan becomes effective (the “Effective Date”). The effectiveness of the Plan shall be subject to approval of the Plan by the stockholders of the
Company within twelve months following the date the Plan is first approved by the Board. No right may be granted under the Plan prior to such stockholder approval. The Plan shall be in effect until the tenth anniversary of the date this Plan is
first approved by the Board, unless sooner terminated under Article 10. No rights may be granted under the Plan during any period of suspension of the Plan or after termination of the Plan. 

ARTICLE XII 
 MISCELLANEOUS 
 12.1 Restriction upon Assignment. A right
granted under the Plan shall not be transferable other than by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant. Except as provided in Section 12.4 hereof, a right
under the Plan may not be exercised to any extent except by the Participant. The Company shall not recognize and shall be under no duty to recognize any assignment or alienation of the Participant’s interest in the Plan, the Participant’s
rights under the Plan or any rights thereunder. 
 12.2 Rights as a Shareholder. With respect to shares of Stock
subject to a right granted under the Plan, a Participant shall not be deemed to be a shareholder of the Company, and the Participant shall not have any of the rights or privileges of a shareholder, until such shares have been issued to the
Participant or his or her nominee following exercise of the Participant’s rights under the Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash securities, or other property) or distribution or other
rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein. 

12.3 Interest. No interest shall accrue on the payroll deductions or lump sum contributions of a Participant under the
Plan. 

  
 12 

 12.4 Designation of Beneficiary. 

(a) A Participant may, in the manner determined by the Administrator, file a written designation of a beneficiary who is to receive any
shares and cash, if any, from the Participant’s account under the Plan in the event of such Participant’s death subsequent to a Purchase Date on which the Participant’s rights are exercised but prior to delivery to such Participant of
such shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant’s account under the Plan in the event of such Participant’s death prior to exercise of the
Participant’s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant’s spouse as his or her beneficiary shall not be effective without the prior
written consent of the Participant’s spouse. 
 (b) Such designation of beneficiary may be changed by the Participant at
any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant’s death, the Company shall deliver such
shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash
to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. 

12.5 Notices. All notices or other communications by a Participant to the Company under or in connection with the Plan shall be
deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. 
 12.6 Equal Rights and Privileges. Subject to Section 6.7, all Eligible Employees of the Company or any Designated Subsidiary will have equal rights and privileges under this Plan so that this
Plan qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Subject to Section 6.7, any provision of this Plan that is inconsistent with Section 423 of the Code will, without further
act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section 423 of the Code. 
 12.7 Use of Funds. All payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate
such payroll deductions. 
 12.8 Reports. Statements of account shall be given to participating Employees at least
annually, which statements shall set forth the amounts of payroll deductions, the Purchase Price, the number of shares purchased and the remaining cash balance, if any. 
 12.9 No Employment Rights. Nothing in the Plan shall be construed to give any person (including any Eligible Employee or Participant) the right to remain in the employ of the Company or any Parent
or Subsidiary or to affect the right of the Company or any Parent or Subsidiary to terminate the employment of any person (including any Eligible Employee or Participant) at any time, with or without cause. 

  
 13 

 12.10 Notice of Disposition of Shares. Each Participant shall give prompt notice to
the Company of any disposition or other transfer of any shares of stock purchased upon exercise of a right under the Plan if such disposition or transfer is made: (a) within two years from the Enrollment Date of the Offering Period in which the
shares were purchased or (b) within one year after the Purchase Date on which such shares were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of
indebtedness or other consideration, by the Participant in such disposition or other transfer. 
 12.11 Governing Law.
The validity and enforceability of this Plan shall be governed by and construed in accordance with the laws of the State of California without regard to otherwise governing principles of conflicts of law. 

  
 14Asset Purchase Agreement

 Exhibit 10.9 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 ASSET PURCHASE AGREEMENT 
 BY AND BETWEEN 
 ARADIGM CORPORATION. 

AND 

SJ2 THERAPEUTICS, INC. 
 Dated as of August 25, 2006 

 TABLE OF CONTENTS 

 

					
	 	  	 	  	Page
		
	ARTICLE I DEFINITIONS	  	1
			
	 Section 1.01
	  	 Certain Definitions
	  	1
	 Section 1.02
	  	 Additional Definitions
	  	6
		
	ARTICLE II ASSIGNMENT TRANSFER AND LICENSE	  	6
			
	 Section 2.01
	  	 Assignment of Assigned Assets to Purchaser
	  	6
	 Section 2.02
	  	 Asset Transfer
	  	6
	 Section 2.03
	  	 Coordination Leads
	  	6
	 Section 2.04
	  	 Transitional Services
	  	7
	 Section 2.05
	  	 Assumption of Liabilities
	  	7
	 Section 2.06
	  	 Consideration
	  	7
	 Section 2.07
	  	 Closing, Closing Place, Time and Date
	  	9
	 Section 2.08
	  	 Nontransferable Assets
	  	10
	 Section 2.09
	  	 FTO Licenses
	  	11
	 Section 2.10
	  	 Taking of Necessary Action; Further Action
	  	11
		
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF ARADIGM	  	12
			
	 Section 3.01
	  	 Organization, Qualification, and Corporate Power
	  	12
	 Section 3.02
	  	 Authorization
	  	12
	 Section 3.03
	  	 Assets
	  	12
	 Section 3.04
	  	 Transferred Books and Records
	  	12
	 Section 3.05
	  	 Transferred Contracts
	  	12
	 Section 3.06
	  	 Transferred Intellectual Property
	  	13
		
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER	  	15
			
	 Section 4.01
	  	 Organization, Qualification, and Corporate Power
	  	15
	 Section 4.02
	  	 Authorization
	  	15
		
	ARTICLE V OTHER AGREEMENTS AND COVENANTS	  	15
			
	 Section 5.01
	  	 Additional Documents and Further Assurances
	  	15
	 Section 5.02
	  	 Reasonable Cooperation of Purchaser
	  	15
	 Section 5.03
	  	 Reasonable Efforts
	  	15
	 Section 5.04
	  	 Indemnification
	  	15
	 Section 5.05
	  	 Covenant Not to Compete
	  	17
		
	ARTICLE VI MISCELLANEOUS	  	17
			
	 Section 6.01
	  	 Press Releases and Public Announcements
	  	17
	 Section 6.02
	  	 No Third-Party Beneficiaries
	  	17

					
	 Section 6.03
	  	 Force Majeure
	  	17
	 Section 6.04
	  	 Limitation of Liability
	  	17
	 Section 6.05
	  	 Entire Agreement and Modification
	  	18
	 Section 6.06
	  	 Amendment
	  	18
	 Section 6.07
	  	 Waivers
	  	18
	 Section 6.08
	  	 Successors and Assigns
	  	18
	 Section 6.09
	  	 Counterparts
	  	18
	 Section 6.10
	  	 Interpretation
	  	18
	 Section 6.11
	  	 Notices
	  	19
	 Section 6.12
	  	 Governing Law
	  	20
	 Section 6.13
	  	 Severability
	  	20
	 Section 6.14
	  	 Construction
	  	20
	 Section 6.15
	  	 Attorneys’ Fees
	  	20
	 Section 6.16
	  	 Further Assurances
	  	20

 EXHIBITS 

 

			
	EXHIBIT A	  	Transferred Assets (including Transferred Technology)
		
	EXHIBIT B	  	Transferred Books and Records
		
	EXHIBIT C	  	Transferred Contracts
		
	EXHIBIT D	  	Transferred Intellectual Property
		
	EXHIBIT E	  	General Assignment and Bill of Sale
		
	EXHIBIT F	  	Assumed Liabilities
		
	EXHIBIT G	  	Transfer Plan
		
	EXHIBIT H	  	Transitional Services Agreement
		
	EXHIBIT I	  	Intraject Delivery System
		
	EXHIBIT J	  	Nontransferable Assets

 ASSET PURCHASE AGREEMENT 

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 25, 2006 by and between
Aradigm Corporation, a California corporation (“Aradigm”), and SJ2 Therapeutics, Inc., a Delaware corporation (“Purchaser”). Aradigm and Purchaser are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

A. Aradigm desires to assign and transfer to Purchaser, and Purchaser desires to accept assignment and transfer from Aradigm, on the
terms and subject to the conditions set forth herein, those certain assets of Aradigm related to the Intraject Delivery System. 

B. Furthermore, Aradigm and Purchaser desire to make certain representations, warranties, covenants and other agreements in connection
with the transactions contemplated hereby. 
 NOW, THEREFORE, in consideration of the covenants and representations set forth
herein, and for other good and valuable consideration, the parties agree as follows: 
 ARTICLE I 

DEFINITIONS 
 Section 1.01 Certain Definitions. As used in this Agreement, the following terms have the following meanings (terms defined in the singular to have a correlative meaning when used in the
plural and vice versa). Certain other terms are defined in the text of this Agreement. 
 (a) “Affiliate” means
a corporation or any other entity that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the designated Party, but only for so long as such control exists. As used in this
definition only, “control” shall mean ownership of shares of stock having at least 50% of the voting power entitled to vote for the election of directors in the case of a corporation (or, in the case of an entity that is not a corporation,
in the election of the corresponding managing authority), or otherwise having the power to directly or indirectly control the management of such entity. 
 (b) “Assigned Assets” shall mean any and all of Aradigm’s right, title and interest in and to the following: 
 (i) any and all tangible assets owned or otherwise transferable by Aradigm as of the Closing Date, in each case to the extent exclusively used or held for use in the Business, including those assets
listed on Exhibit A (collectively, “Transferred Assets”); 
 (ii) the Books and Records listed on
Exhibit B (collectively, “Transferred Books and Records”); 
  

 1 

 (iii) all agreements listed on Exhibit C (collectively, “Transferred
Contracts”); 
 (iv) all Patents (including in each case all rights to Prosecute and Enforce the same) listed on
Exhibit D (collectively, “Transferred Patents”); 
 (v) all Trademarks (including in each case all
rights to Prosecute and Enforce the same) listed on Exhibit D (collectively, “Transferred Trademarks”); 

(vi) any and all Technology owned or otherwise transferable by Aradigm as of the Closing Date, other than the Transferred Patents and
Transferred Trademarks, in each case to the extent exclusively used or held for use in the Business, including that Technology listed on Exhibit A (collectively, “Transferred Technology”); and 

(vii) any and all right to recover past, present and future damages for the breach, infringement or misappropriation, as the case may be,
of any of the foregoing. 
 (c) “Books and Records” shall mean all papers and records (in any format including
paper or electronic) kept or maintained including any and all laboratory notebooks, invention disclosures, purchasing and sales records, all data and communications relating to ongoing business development activities, preclinical and clinical data,
all Regulatory Documents, vendor lists, accounting and financial records, product documentation, product specifications, marketing documents and the like, in each case pertaining to the Business or the Assigned Assets. 

(d) “Business” shall mean the research, development, commercialization, manufacture, marketing, distribution, sale,
support and other use and commercial exploitation of the Intraject Delivery System. 
 (e) “Business Intellectual
Property” shall mean any and all Technology and any and all Intellectual Property Rights, including Registered Intellectual Property Rights, that is or are owned (in whole or in part) by or exclusively licensed to Aradigm, as of the Closing
Date, in each case that are used in or necessary to the Business. 
 (f) “Dollars” shall refer to United States
currency unless expressly specified otherwise. 
 (g) “Governmental Body” shall mean any: (i) nation,
province, state, county, city, town, village, district, or other jurisdiction of any nature; (ii) federal, provincial, state, local, municipal, foreign, or other government; (iii) governmental or quasi-governmental authority of any nature
(including any governmental agency, branch, department, official, or entity and any court or other tribunal); (iv) multi-national organization or body; or (v) body exercising, or entitled to exercise, any administrative, executive,
judicial, legislative, police, regulatory, or taxing authority or power of any nature. 
 (h) “Intraject Delivery
System” shall mean Aradigm’s Intraject® needle-free injection delivery system as more fully described in Exhibit I (the “Existing Delivery System”) or any modified, improved or derivative version thereof, in each
case that includes one or more material elements of the Existing Delivery System. 
  

 2 

 (i) “Intellectual Property Rights” shall mean any or all of the following
and all rights in, arising out of, or associated therewith: (i) all United States and foreign patents and utility models and applications therefor and all reissues, divisionals, re examinations, renewals, extensions, provisionals, supplementary
protection certificates, continuations and continuations in-part thereof, and equivalent or similar registered rights anywhere in the world (“Patents”); (ii) all trade secrets and other rights in know-how and confidential or
proprietary information, inventions and discoveries, including without limitation invention disclosures; (iii) all copyrights, works of authorship, copyright registrations and applications therefor and all other rights corresponding thereto
throughout the world (“Copyrights”); (iv) all rights in Uniform Resource Locators, World Wide Web addresses and domain names and applications and registrations therefor (“Internet Property Rights”);
(v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefor and all goodwill associated therewith throughout the world (“Trademarks”); and
(vi) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world, including, without limitation, moral rights. 
 (j) “Licensee” shall mean a Person other than an Affiliate to whom Purchaser or its Affiliate has granted the right, or to whom such a Person has sublicensed the right, to (i) make
and sell any Product or (ii) sell any Product, provided that distributors, wholesalers and resellers as to which Purchaser does not receive compensation on resales of Products by such entity shall not be considered Licensees. 

(k) “Lien” shall mean any mortgage, pledge, lien, charge, claim, security interest, adverse claims of ownership or use,
restrictions on transfer, defect of title or other encumbrance of any sort, other than (i) mechanic’s, materialmen’s, and similar liens with respect to any amounts not yet due and payable, and (ii) liens for taxes not yet due and
payable. 
 (l) “Net Sales” shall mean the amounts actually received by Purchaser, its Affiliates, or
Licensees, in consideration of their sales of Product to Third Party customers, less: (i) normal and customary trade, cash and other discounts; (ii) credits or allowances for damaged goods, returns, rejections or recalls of Product;
(iii) sales taxes, value added taxes, withholding, import/export taxes or other similar taxes (excluding taxes on the income of the selling entity) actually paid; (iv) normal and customary charge back payments or rebates; and
(v) packaging, handling fees, prepaid freight, insurance and the like to the extent separately identified on the invoice. Sales between or among Purchaser, its Affiliates or Licensees for resale shall be excluded from the computation of Net
Sales, but the subsequent re sale of such Products by Purchaser, its Affiliates or Licensees to an end user shall be included within the computation of Net Sales. Net Sales shall not include amounts in respect of Product sold or used for development
applications (including for clinical trials) or commercial samples (i.e., items provided for free or at or below cost plus a nominal profit for promotional purposes). 
 (m) “Nontransferable Asset” shall have the meaning ascribed to the term in Section 9. 
  

 3 

 (n) “Non-Sumatriptan Product” shall mean any Product comprising the
Intraject Delivery System combined with an applicable drug formulation, other than Sumatriptan. 
 (o) “Person”
shall mean any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, Governmental Body or other entity.

 (p) “Product” shall mean any pharmaceutical product comprising the Intraject Delivery System combined with
Sumatriptan or other applicable drug formulation. 
 (q) “Prosecution and Enforcement” shall mean (i) the
preparation, filing for, prosecution, maintenance of registrations thereof and applications for any such registration (ii) the conduct of interferences, re examinations, reissues, oppositions or requests for term extensions with respect thereto
and (iii) the conduct of any enforcement proceeding with respect thereto (whether infringement, misuse, misappropriation or otherwise) or any declaratory judgment proceeding with respect thereto; and “Prosecute and Enforce”
shall have the correlative meaning. 
 (r) “Pulmonary Field” shall mean the delivery of one or more aerosolized
active pharmaceutical ingredients directly into the bronchia or lungs. 
 (s) “Registered Intellectual Property
Rights” shall mean all United States, international and foreign: (i) Patents, including applications therefor (each a “Registered Patent”); (ii) registered Trademarks, applications to register Trademarks, including
intent-to use applications, or other registrations or applications related to Trademarks; (iii) Copyright registrations and applications to register Copyrights; and (iv) any other Technology or Intellectual Property Rights that is the
subject of an application, certificate, filing, registration or other document issued by, filed with, or recorded by, any state, government or other public or private legal authority at any time. 

(t) “Regulatory Documents” shall mean any and all regulatory submissions (whether completed or in process) to any
Governmental Body anywhere in the world submitted by or on behalf of Aradigm relating to the Business (including any product developed in connection therewith), including all annual reports, adverse event reports, and other adverse event submission
tracking information, and amendments and supplements to any of the foregoing. For purposes of clarity, “Regulatory Documents” shall not include any filing or other submission made to the United States Securities and Exchange Commission,
the National Association of Securities Dealers, the Nasdaq Stock Exchange or any similar entity. 
 (u)
“Representatives” shall mean, with respect to a Person, that Person’s officers, directors, employees, accountants, counsel, investment bankers, financial advisors, agents and other representatives. 

 

 4 

 (v) “Royalty Revenue” shall mean running royalties actually received by
Purchaser from a Licensee for sales of Non-Sumatriptan Products by or under authority of such Licensee, plus any license fees or milestone or other payments receive by Purchaser from a Licensee to the extent not allocable to recovery of development
or other costs incurred by Purchaser specific to the applicable Product. For clarity, Royalty Revenue shall exclude: (i) payments in consideration of goods (including Products) or services at Purchaser’s fully-burdened cost therefor (any
amounts in excess of the fully-burdened cost shall be included in Royalty Revenue), (ii) payments in consideration for equity at the fair market value therefor (any amounts in excess of the fair market value shall be included in Royalty
Revenue) and (iii) amounts received by Purchaser in consideration for a sale of all, or substantially all, of the business or assets of Purchaser (whether by way of merger, sale of stock, sale of assets or otherwise), if the successor to such
business or assets has assumed the obligations under Section 2.06(a) of this Agreement. 
 (w) “Royalty
Term” shall mean, for a given Product, the period commencing on the Closing Date and continuing until the later of (i) the ten-year anniversary of the first commercial sale of such Product in the United States, but no more than twenty
years after the Closing Date and (ii) the later of expiration or abandonment of the last Valid Claim of the Transferred Patents covering the manufacture, use or sale of such Product. 

(x) “Sumatriptan Product” shall mean any Product comprising the Intraject Delivery System combined with Sumatriptan.

 (y) “Technology” shall mean any or all of the following: (i) works of authorship including, without
limitation, computer programs, source code and executable code, whether embodied in software, firmware or otherwise, documentation, designs, files, net lists, records, data and mask works; (ii) inventions (whether or not patentable),
improvements, and technology; (iii) proprietary and confidential information, including technical data and customer and supplier lists, trade secrets and know how; (iv) databases, data compilations and collections and technical data;
(v) logos, trade names, trade dress, trademarks, service marks; (vi) World Wide Web addresses, domain names and sites; (vii) protocols, methods and processes; and (viii) all instantiations of the foregoing in any form and
embodied in any media. 
 (z) “Territory” shall mean the entire world. 

(aa) “Third Party” shall mean any Person other than Purchaser or Aradigm, or their respective Affiliates. 

(bb) “Transfer Plan” shall mean the plan for the transfer of the Assigned Assets attached hereto as Exhibit G.

 (cc) “Valid Claim” shall mean (i) a claim of an issued and unexpired patent, which has not been held
unenforceable, unpatentable or invalid by a court or other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a claim in a pending
patent application being prosecuted in good faith that has not been abandoned or finally rejected and that has been pending for fewer than five years after the earliest priority date to which it is entitled. 

 

 5 

 Section 1.02 Additional Definitions. Each of the following definitions shall
have the meanings defined in the corresponding sections of this Agreement indicated below: 
  

					
	 Definition
	 	 Section
	 	 
	Agreement	 	Preamble	 	
	Aradigm Indemnities	 	Section 6.04(b)	 	
	Assumed Liabilities	 	Section 2.05(b)	 	
	Claim	 	Section 6.04(a)	 	
	Closing Date	 	Section 2.07	 	
	Coordination Lead	 	Section 2.03	 	
	Excluded Liabilities	 	Section 2.05(c)	 	
	Indemnitee	 	Section 6.04(c)	 	
	Indemnitor	 	Section 6.04(c)	 	
	Party	 	Preamble	 	
	PTO	 	Section 4.06(a)	 	
	Purchaser Indemnities	 	Section 6.04(a)	 	

 ARTICLE II 
 ASSIGNMENT, TRANSFER AND LICENSE 
 Section 2.01 Assignment of
Assigned Assets to Purchaser. Upon the terms and subject to the conditions set forth herein, Aradigm hereby assigns, conveys and transfers to Purchaser, at the Closing, all of Aradigm’s right, title and interest in and to the Assigned
Assets, subject to the reservation on behalf of Aradigm of a perpetual, worldwide, royalty-free, non-exclusive license, under the Transferred Patents and Transferred Technology solely for purposes of the Pulmonary Field, which retained license shall
include the right to grant sublicenses to Persons solely within the scope of such retained license in connection with the grant to such Persons of licenses under other Patents owned or controlled by Aradigm. 

Section 2.02 Asset Transfer. Subject to the terms and conditions set forth in this Agreement, on the Closing Date, Aradigm
shall transfer all Assigned Assets, in the shape, manner and form of their existence as of the date such Assigned Assets are transferred to Purchaser, in accordance with the Transfer Plan. Without limiting the specifics of the Transfer Plan, Aradigm
shall promptly transfer those assets (to the extent not previously transferred to the Transferee hereunder) to Purchaser as required in the Transfer Plan and this Section 2.02. Unless otherwise specified in the Transfer Plan, the mode of such
transfer shall be determined by the Coordination Leads with the goal of efficiency and cost-effectiveness. Without limiting the foregoing and in connection with such transfers of assets pursuant to this Section 2.02, Aradigm shall make
available such personnel reasonably familiar with the Assigned Assets to consult with and assist Purchaser in implementing such assets at mutually agreeable times. 
 Section 2.03 Coordination Leads. In order to facilitate the transfer of assets pursuant to Section 2.02, each Party shall appoint, from time to time, by written notice to the other Party,
one of its personnel as its coordination lead (each, a “Coordination Lead”). The Coordination Leads shall be responsible for oversight and coordination of the transfer of assets in accordance with Section 2.02 and the Transfer
Plan. The Coordination Leads shall carry out their responsibilities by any reasonable means or practices as the Parties may mutually agree. 
  

 6 

 Section 2.04 Transitional Services. Aradigm shall provide all reasonable
transitional services to Purchaser, including facilities, furnishings, access to systems, document control, quality systems, IT support, accounting, payroll, administration and other such services as the Parties may mutually agree, until
December 31, 2006 or until such later date as mutually agreed to by the Parties, as more fully described in Exhibit H, and Purchaser shall pay the fees therefor set forth in Exhibit H in accordance with the schedule set forth
therein. 
 Section 2.05 Assumption of Liabilities. 

(a) Assumption. Upon the terms and subject to the conditions set forth herein, at the Closing, Purchaser shall assume from
Aradigm, and Aradigm shall irrevocably convey, transfer and assign to Purchaser, all of the Assumed Liabilities (as defined in Section 2.05(b) hereof). Purchaser shall not assume any liabilities of Aradigm pursuant hereto, other than the
Assumed Liabilities. 
 (b) Definition of Assumed Liabilities. For all purposes of and under this Agreement, the term
“Assumed Liabilities” shall mean, refer to and include only those liabilities listed on Exhibit F. 

(c) Definition of Excluded Liabilities. Except for the Assumed Liabilities, Purchaser does not assume and is not assuming any
debt, liability, duty or other obligation (of any kind) of Aradigm, whether known or unknown, fixed or contingent, and regardless of when such liabilities or obligations may arise or may have arisen or when asserted, including any liabilities, or
obligations related to the Assigned Assets which are outstanding or unpaid as of the Closing (the “Excluded Liabilities”), and Aradigm shall remain responsible for the Excluded Liabilities. 

Section 2.06 Consideration. On the terms and subject to the conditions set forth in this Agreement, in addition to the
payments contemplated by Section 2.07(a), the consideration for the Assigned Assets shall be the following: 
 (a)
Royalties. 
 (i) In consideration for the assignment and transfer of the Assigned Assets, with respect to Net Sales Purchaser
shall pay to Aradigm, during the Royalty Term: 
 (1) For each Non-Sumatriptan Product, [***] percent ([***]%) of Net Sales of
such Non-Sumatriptan Product, provided that in the event and to the extent such Non-Sumatriptan Product is commercialized by a Licensee Purchaser may at its election pay to Aradigm either [***] percent ([***]%) of such Licensee’s Net Sales of
such Non-Sumatriptan Product or [***] percent ([***]%) of Purchaser’s Royalty Revenues from such Licensee in respect of such Non-Sumatriptan Product. Purchaser shall make its election with respect to each such Non-Sumatriptan Product by written
notice to Aradigm of its election on or before the date its first payment would be due under Section 2.06(a)(vi) in respect of such Non-Sumatriptan Product under either of the foregoing alternatives. 

(2) For Sumatriptan Products, [***] percent ([***]%) of Net Sales of Sumatriptan Products. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 7 

 (ii) Combination Products. In the event that a Product is sold in the form of a
combination product (a “Combination Product”) containing both (1) such Product and (2) another product or service for which no royalty would be due hereunder if sold separately, the Net Sales from such combination sales
for purposes of calculating the amounts due under this Section 2.06(a) shall be calculated by multiplying Net Sales of the Combination Product by a fraction that reasonably reflects the fair value of the contribution of the Product in the
Combination Product to the total market value of such Combination Product, which fraction shall be established by the Purchaser and Aradigm through good faith negotiations and mutual agreement, on a Combination Product-by-Combination Product basis.

 (iii) Single Royalty. Only one royalty shall be paid with respect to each unit of Product that is subject to royalties
under this Section 2.06(a), without regard to the number of transfers or otherwise. In no event shall more than one royalty be due under this Section 2.06(a) with respect to any Product unit. 

(iv) Milestone Payment. Purchaser shall pay Aradigm $4,000,000 within 30 days of the first U.S. commercial sale of the Sumatriptan
Product. 
 (v) Records. During the term of this Agreement and for a period of three years thereafter, Purchaser and its
Affiliates shall keep, and shall cause its licensees and sublicensees to keep, complete and accurate records of their Net Sales in sufficient detail to enable the amounts payable under this Section 2.06(a) to be determined. Upon Aradigm’s
written request, but not more frequently than once per calendar year, Purchaser shall permit representatives or agents of Aradigm, at Aradigm’s expense, to examine such records during Purchaser’s regular business hours for the purpose of
and to the extent necessary to verify any report required under this Agreement with respect to Net Sales received not more than three years prior to the date of Aradigm’s request. In the event that the amounts due to Aradigm are determined to
have been underpaid, Purchaser shall promptly pay to Aradigm any amount due and unpaid. In the event that it is determined, as a result of such examination, that the amount underpaid with respect to a given payment is in excess of 5% of the total
amount of such payment, then Purchaser shall reimburse Aradigm for all costs incurred by Aradigm in conducting such examination. 
 (vi) Reports. Beginning with the first accrual of royalties or other payments due hereunder, Purchaser shall provide to Aradigm a quarterly royalty report as follows: Within 60 days after the end
of each quarterly period, Purchaser shall deliver to Aradigm a true and accurate report, giving such particulars of the business conducted by Purchaser, its Affiliates and Licensees, during such quarterly period as are pertinent to account for
payments due under this Section 2.06(a). Such report shall include, as applicable, at least (A) the total of Net Sales during such quarterly period; (B) the calculation of royalties; (C) the calculation of Royalty Revenue for
each applicable Non-Sumatriptan Product and (D) the total royalties and other payments due Aradigm. Simultaneously with the delivery of each such report, Purchaser shall pay to Aradigm the total amount, if any, due to Aradigm for the period of
such report. If no payment is due, Purchaser shall so report. Aradigm shall not provide to Third Parties any information contained in reports provided to Aradigm under this Section 2.06(a)(v), or learned by Aradigm under
Section 2.06(a)(iii) above. 
  

 8 

 (vii) Payments. All amounts payable hereunder by Purchaser shall be payable in
Dollars to Aradigm. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rates reported in the Wall Street Journal on the last business day of the
quarter in respect of which such payment is made. 
 (viii) Taxes. Any withholding or other tax that is required by law
to be withheld on behalf of Aradigm with respect to payments owed by Purchaser pursuant to this Agreement shall be deducted by Purchaser from such payment prior to remittance. Purchaser shall promptly furnish Aradigm evidence of any such taxes
withheld. 
 (ix) Without limiting Section 2.06(a)(v) above, Purchaser shall take reasonable measures to keep Aradigm
informed as to the progress of the development and commercialization of the Intraject Delivery System and Products arising therefrom until such time as Purchaser has fulfilled its royalty obligations to Aradigm pursuant to Section 2.06(a).

 Section 2.07 Closing, Closing Place, Time and Date. The closing of the transactions contemplated by this
Agreement (the “Closing”) shall be held at the offices of Cooley Godward llp, 3175 Hanover Street, Palo Alto, California, at 10:00 a.m. on the date of the Agreement (the actual date on which the Closing shall occur being referred to herein
as the “Closing Date”). 
 (a) Closing Deliveries. 

(i) At the Closing, Purchaser shall deliver, or cause to be delivered, to Aradigm the following, dated as of the date of this Agreement
and, where relevant, executed for and on behalf of Purchaser by a duly authorized officer thereof: 
 (1) any and all
instruments, certificates and agreements as Aradigm may reasonably request in order to effectively make Purchaser responsible for all Assumed Liabilities pursuant hereto to the fullest extent permitted by applicable law; 

(2) Purchaser shall have provided Aradigm with evidence demonstrating that Purchaser has obtained at least $15 million in equity
financing; 
 (3) Purchaser shall have paid to Aradigm, by wire transfer, $4,000,000 in cash; 

(4) Purchaser shall have reimbursed Aradigm for all documented expenses actually incurred by Aradigm from July 1, 2006 through the
Closing Date, that were pre-approved in writing by Purchaser, up to $515,036; 
 (5) Each of Steve Farr and John Turanin shall
have provided Aradigm with a release of all claims over or rights to any severance payments relating to their cessation of services to Aradigm, in a form that is reasonably acceptable to Aradigm and including mutually agreed consideration for such
releases; and 
  

 9 

 (6) the Transitional Services Agreement. 

(ii) At the Closing, Aradigm shall deliver, or cause to be delivered, to Purchaser the following, dated as of the date of this Agreement
and executed for and on behalf of Aradigm by a duly authorized officer thereof: 
 (1) a general assignment and bill of sale
with respect to the Assigned Assets in the form attached hereto as Exhibit F; 
 (2) one or more instruments of
assignment and assumption, in customary form and substance reasonably satisfactory to Purchaser and Aradigm and their respective counsel; 
 (3) an instrument of assignment of the Transferred Patents, the Transferred Trademarks, and any other Registered Intellectual Property Rights included in the Assigned Assets, in customary form and
substance reasonably satisfactory to Purchaser and Aradigm and their respective counsel; 
 (4) any and all required third
party consents including those consents necessary for the valid assignment and transfer of the Transferred Contracts; 
 (5)
any and all other instruments, certificates and agreements as Purchaser may reasonably request in order to effectively transfer to Purchaser all of the Assigned Assets pursuant hereto and to the Transfer Plan to the fullest extent permitted by
applicable law; and 
 (6) the Transitional Services Agreement. 

(b) Closing. From and after the Closing, the Assigned Assets shall be held for the account and benefit, and at the risk, of
Purchaser. 
 Section 2.08 Nontransferable Assets. To the extent that any Assigned Asset or Assumed Liability to be
sold, conveyed, assigned, transferred, delivered or assumed to or by Purchaser pursuant hereto, or any claim, right or benefit arising thereunder or resulting therefrom, is not capable of being sold, conveyed, assigned, transferred or delivered
without the approval, consent or waiver of the issuer thereof or the other Party thereto, or any third Person (including a Governmental Body), or if such sale, conveyance, assignment, transfer or delivery or attempted sale, conveyance, assignment,
transfer or delivery would constitute a breach (or give rise to a termination right) thereof or a violation of any law, decree, order, regulation or other governmental edict (collectively, with respect to such Assigned Assets, as set forth on
Exhibit J, the “Nontransferable Assets”), except as expressly otherwise provided herein, this Agreement shall not constitute a sale, conveyance, assignment, transfer or delivery thereof, or an attempted sale, conveyance,
assignment, transfer or delivery thereof absent such approvals, consents or waivers. If any such approval, consent or waiver shall not be obtained, or if an attempted assignment of any such Assigned Asset or the assumption of any Assumed Liability
by Purchaser would be ineffective so that Purchaser would not in fact receive all the Nontransferable Assets or assume all such Assumed Liabilities pursuant hereto, Aradigm and Purchaser shall cooperate in a mutually agreeable arrangement under
which Purchaser would obtain the benefits and assume the obligations of such Assigned Assets and Assumed Liabilities, respectively, in accordance with this Agreement, including subcontracting, sub-licensing, or sub-leasing to Purchaser, or under
which Aradigm, at Purchaser’s expense, would enforce for the benefit of Purchaser, with Purchaser assuming all of Aradigm’s obligations thereunder, any and all rights of Aradigm against a Third Party thereto. 

 

 10 

 Section 2.09 FTO Licenses. 

(a) To Purchaser. Aradigm hereby grants to Purchaser a non-exclusive, fully-paid, world-wide, perpetual, irrevocable,
transferable, sublicensable license to fully exercise any Intellectual Property Rights that are (i) owned, controlled or employed by Aradigm at any time prior to the Closing (or that arises thereafter to the extent covering Technology created,
owned, controlled or employed by Aradigm prior to the Closing), (ii) necessary or useful for the operation of the Business and (iii) not included in the Assigned Assets that are actually assigned to Purchaser. 

(b) To Aradigm. Purchaser hereby grants to Aradigm a non-exclusive, fully-paid, world-wide, perpetual, irrevocable, transferable,
sublicensable license to fully exercise any Intellectual Property Rights that are (i) owned, controlled or employed by Purchaser as of the Closing (or that arises thereafter to the extent covering Technology created, owned, controlled or
employed by Aradigm as of the Closing) and (ii) solely for use in the Pulmonary Field. 
 Section 2.10 Taking of
Necessary Action; Further Action. From time to time after the Closing, at the request of either Party, the Parties hereto shall execute and deliver such other instruments of sale, transfer, conveyance, assignment and confirmation and take such
action as the Parties may reasonably determine is necessary to transfer, convey and assign to Purchaser, and to confirm Purchaser’s title to or interest in the Assigned Assets, to put Purchaser in actual possession and operating control thereof
and to assist Purchaser in exercising all rights with respect thereto. Aradigm hereby constitutes and appoints Purchaser and its successors and assigns as its true and lawful attorney in fact in connection with the transactions contemplated by this
Agreement, with full power of substitution, in the name and stead of Aradigm but on behalf of and for the benefit of Purchaser and its successors and assigns, to demand and receive any and all of the Assigned Assets and to give receipt and releases
for and in respect of the same and any part thereof, and from time to time to institute and prosecute, in the name of Aradigm or otherwise, for the benefit of Purchaser or its successors and assigns, proceedings at law, in equity, or otherwise,
which Purchaser or its successors or assigns reasonably deem proper in order to collect or reduce to possession or endorse any of the Assigned Assets and to do all acts and things in relation to the Assigned Assets which Purchaser or its successors
or assigns reasonably deem desirable. 
  

 11 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF ARADIGM 
 Aradigm hereby represents and
warrants to Purchaser as follows: 
 Section 3.01 Organization, Qualification, and Corporate Power. Aradigm
(a) is a corporation duly organized, validly existing, and in good standing under the laws of the State of California, (b) has obtained all necessary corporate approvals to enter into and execute this Agreement and (c) has the full
right, power and authority to enter into this Agreement. 
 Section 3.02 Authorization. Aradigm has full power and
authority to execute and deliver this Agreement, and to consummate the transactions contemplated hereunder and to perform its obligations hereunder, and no other proceedings on the part of Aradigm are necessary to authorize the execution, delivery
and performance of this Agreement. This Agreement constitutes the valid and legally binding obligations of Aradigm, enforceable against Aradigm in accordance with its terms and conditions, except as such enforceability may be limited by principles
of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies. 

Section 3.03 Assets. The Assigned Assets include all assets of Aradigm and its Affiliates that are used or held for use by
Aradigm and its Affiliates primarily in the operation or conduct of the Business. 
 (a) The Assigned Assets include all assets
of Aradigm and its Affiliates that are used or held for use by Aradigm and its Affiliates primarily in the operation or conduct of the Business. 
 (b) Following the consummation of the transactions contemplated by this Agreement and the related agreements, and the execution of the instruments of transfer contemplated hereby and thereby, Purchaser
will own, with good, valid and marketable title, or lease, under valid and subsisting leases, or otherwise acquire the interests of Aradigm in the Assigned Assets, free and clear of any Liens, and without incurring any penalty or similar transfer
fee. 
 Section 3.04 Transferred Books and Records. The Transferred Books and Records listed on Exhibit B are
all of the Books and Records maintained by Aradigm that pertain to the Business and the Assigned Assets. 
 Section 3.05
Transferred Contracts. The Transferred Contracts listed on Exhibit C are all of the contracts between Aradigm and any Third Party currently necessary for or primarily related to, the operation of the Business, and true and
complete copies of all such Transferred Contracts have been delivered or made available to Purchaser or its representatives. Each Transferred Contract is in full force and effect and, to Aradigm’s knowledge, Aradigm is not subject to any
default thereunder, nor, to Aradigm’s knowledge, is any party obligated to Aradigm pursuant to any such Transferred Contract subject to any default thereunder. Aradigm has neither breached, violated or defaulted under, nor received notice that
Aradigm has breached, violated or defaulted under, any of the terms or conditions of any Transferred Contract. Aradigm has obtained, or will obtain prior to the Closing, all necessary consents, waivers and approvals of parties to any Transferred
Contract as are required thereunder in connection with the Closing, or for any such Transferred Contract to be transferred to Purchaser, and to remain in full force and effect without limitation, modification or alteration after the Closing.
Following the Closing, Purchaser will be permitted to exercise all of the rights Aradigm had under the Transferred Contracts without the payment of any additional amounts or consideration other than ongoing fees, royalties or payments which Aradigm
would otherwise be required to pay pursuant to the terms of such Transferred Contracts had the transactions contemplated by this Agreement not occurred. 
  

 12 

 Section 3.06 Transferred Intellectual Property. 

(a) The Exhibits listing the Transferred Patents and the Transferred Trademarks are, to Aradigm’s knowledge, complete and accurate.
With respect to Transferred Patents, those Transferred Patents that are Registered Patents are currently in compliance with formal legal requirements (including payment of filing, examination and maintenance fees and proofs of use), and are not
subject to any unpaid maintenance fees or taxes falling due within 90 days after the Closing Date. There are no proceedings or actions known to Aradigm before any court, tribunal (including the United States Patent and Trademark Office (the
“PTO”) or equivalent authority anywhere in the world) related to any such Registered Patent. 
 (b) To
Aradigm’s knowledge, each Registered Patent that is a Transferred Patent is properly filed and is currently pending or issued, and all necessary registration, maintenance and renewal fees in connection with such Registered Patent that is a
Transferred Patent have been paid and all necessary documents and certificates in connection with such Registered Patent have been filed with the relevant patent authorities in the United States or foreign jurisdictions in which Aradigm has elected
to pursue such Registered Patent, as the case may be, for the purposes of maintaining such Registered Patent. There are, to Aradigm’s knowledge, no actions that must be taken by Aradigm within 90 days after the Closing Date, including the
payment of any registration, maintenance or renewal fees or the filing of any responses to PTO office actions, documents, applications or certificates for the purposes of obtaining, maintaining, perfecting or preserving or renewing any such
Registered Patent. To the extent Aradigm has acquired from any Person any Technology or Intellectual Property Right, in each case that are included in the Assigned Assets, Aradigm has obtained a valid and enforceable assignment sufficient to
irrevocably transfer all rights in such Technology and Intellectual Property Rights (including the right to seek past and future damages with respect thereto) to Aradigm. To the maximum extent provided for by, and in accordance with, applicable laws
and regulations, Aradigm has recorded each such assignment of a Registered Intellectual Property Right assigned to Aradigm with the relevant Governmental Body, including the PTO, the U.S. Copyright Office, or their respective equivalents in any
relevant foreign jurisdiction, as the case may be. Aradigm has not claimed a particular status, including “Small Entity Status,” in the application for any Registered Patent that is a Transferred Patent, which claim of status was not at
the time made, or which has since become, inaccurate or false or that will no longer be true and accurate as of the Closing Date. 
 (c) Aradigm has no knowledge of any misrepresentation regarding, or failure to disclose, any fact or circumstances in any application for any Registered Patent that is a Transferred Patent that would
materially and adversely affect the validity or enforceability of such Registered Patent that is a Transferred Patent. 
  

 13 

 (d) All Registered Intellectual Property Rights included in the Assigned Assets are free and
clear of any Liens. Immediately prior to the Closing, Aradigm is the exclusive owner or exclusive licensee of all Business Intellectual Property. 
 (e) Schedule 3.06(e) sets forth a list of all Regulatory Documents. 
 (f) All
Assigned Assets will be fully transferable, alienable or licensable by Purchaser without restriction and without payment of any kind to any Third Party, including royalty obligations, other than those restrictions and payments Aradigm would be
subject to as of the Closing Date with respect to such Assigned Assets had the transactions contemplated by this Agreement not occurred. 
 (g) Each material item of Technology used in the conduct of the Business by Aradigm was (i) written and created by then-current employees of Aradigm acting within the scope of their employment or
(ii) acquired or licensed by Aradigm from Third Parties who have validly and irrevocably assigned such item to Aradigm, or granted Aradigm a license to use such item of a sufficient scope to cover Aradigm’s use or prior use of thereof in
the Business. 
 (h) To Aradigm’s knowledge, the conduct of the Business by Aradigm as it was previously conducted does
not, infringe or misappropriate any Intellectual Property Right of any person, or constitute unfair competition or trade practices under the laws of any jurisdiction, and Aradigm has not received notice from any person claiming that such conduct by
Aradigm infringes or misappropriates any Intellectual Property Right of any person or constitutes unfair competition or trade practices under the laws of any jurisdiction. 
 (i) Each employee and consultant of Aradigm that provides services to Aradigm in connection with the Business has entered into a valid and binding written agreement with Aradigm sufficient to vest title
in Aradigm of all Technology and Intellectual Property Rights included in the Assigned Assets and created by such employee or consultant in the scope of his or her services or employment for Aradigm. 

(j) Aradigm has not transferred ownership of, nor granted any exclusive license of or exclusive right to use, or authorized the retention
of any exclusive rights to use or joint ownership of, any Technology or Intellectual Property Right that is or was used in connection with the Business, to any other person. 
 (k) To Aradigm’s knowledge, no person is infringing or misappropriating any Intellectual Property Right included in the Assigned Assets. 

(l) No Business Intellectual Property is subject to any proceeding or outstanding decree, order, judgment or settlement agreement or
stipulation against Aradigm or, to Aradigm’s knowledge, against any Third Parties from whom Aradigm acquired or licensed Business Intellectual Property that restricts in any material way the use, transfer or licensing of such Business
Intellectual Property by Aradigm or is reasonably likely to affect the validity, use or enforceability of such Business Intellectual Property. 
  

 14 

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF PURCHASER 
 Purchaser hereby represents and warrants to
Aradigm as follows: 
 Section 4.01 Organization, Qualification, and Corporate Power. Purchaser (a) is a
corporation duly organized, validly existing, and in good standing under the laws of the State of [Delaware], (b) has obtained all necessary corporate approvals to enter into and execute this Agreement and (c) has the full right, power and
authority to enter into this Agreement. 
 Section 4.02 Authorization. Purchaser has full power and authority to
execute and deliver this Agreement, and to consummate the transactions contemplated hereunder and to perform its obligations hereunder, and no other proceedings on the part of Purchaser are necessary to authorize the execution, delivery and
performance of this Agreement. This Agreement constitutes the valid and legally binding obligations of Purchaser, enforceable against Purchaser in accordance with its terms and conditions, except as such enforceability may be limited by principles
of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies. 

ARTICLE V 

OTHER AGREEMENTS AND COVENANTS 
 Section 5.01 Additional Documents and Further Assurances. Each Party hereto, at the request of another Party hereto, shall execute and deliver such other instruments and do and perform such
other acts and things as may be reasonably requested for effecting completely the consummation of the transactions contemplated hereby. 
 Section 5.02 Reasonable Cooperation of Purchaser. Purchaser shall cooperate, to the extent reasonable, with Aradigm’s efforts to obtain any Third Party consents; provided, however, that
this Section 6.02 shall not obligate Purchaser to incur any additional expense or liability. 
 Section 5.03
Reasonable Efforts. Each of the Parties will use their reasonable efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement.

 Section 5.04 Indemnification. 
 (a) Indemnification of Purchaser. 
 (i) Aradigm shall indemnify and hold harmless
each of Purchaser and its Affiliates, and the directors, officers, and employees of Purchaser and of such Affiliates, and the successors and assigns of any of the foregoing (collectively, the “Purchaser Indemnitees”), from and
against any and all liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of settlement) (any of the foregoing, a
“Claim”) incurred by any Purchaser Indemnitee, based upon a Claim of a Third Party, to the extent resulting from the breach of any of Aradigm’s express representations and warranties set forth in Article III of this Agreement.
Aradigm’s obligations to the Purchaser Indemnitees pursuant to this Section 5.04(a)(i) shall be limited, in the aggregate, to amounts actually received by Aradigm by operation of Section 2.06(a)(i). Notwithstanding the foregoing,
Aradigm shall not have any obligation to the Purchaser Indemnitees in respect of any breach of representations and warranties as to which Purchaser has actual knowledge (including for this purpose the actual knowledge of Steve Farr, John Turanin or
Jonathan Rigby) prior to the Closing. 
  

 15 

 (b) Aradigm shall indemnify and hold harmless the Purchaser Indemnitees from and against all
Claims arising from the Excluded Liabilities. 
 (c) Indemnification of Aradigm. Purchaser shall indemnify and hold
harmless each of Aradigm and its Affiliates, and the directors, officers, and employees of Aradigm and of such Affiliates, and the successors and assigns of any of the foregoing (collectively, the “Aradigm Indemnitees”), from and
against any and all liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of settlement) incurred by any Aradigm Indemnitee,
based upon (i) a Claim of a Third Party, to the extent resulting from the breach of any of Purchaser’s express representations and warranties set forth in Article IV of this Agreement, (ii) a Claim relating to product liability
concerning any of the Assigned Assets or (iii) a Claim relating to the Assumed Liabilities. 
 (d) Procedure. A
Party that intends to claim indemnification under this Section 5.04 (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any Claim in respect of which the Indemnitee intends
to require such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the
defense and/or settlement of such Claim. The indemnification obligations of the Parties in this Section 5.04 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which
consent shall not be unreasonably withheld or delayed. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such Claim, if prejudicial to Indemnitor’s ability to defend such action,
shall relieve such Indemnitor of any liability to the Indemnitee under this Section 5.04, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability to any Indemnitee otherwise than under
this Section 5.04. The Indemnitee under this Section 5.04 and its directors, officers and employees shall cooperate fully with the Indemnitor and its legal representatives and provide full information in the investigation of any Claim
covered by this indemnification. 
 (e) Sole Remedy. The indemnification rights provided for in this Article V shall
constitute the sole and exclusive remedy and the sole basis and means of recourse among the Aradigm Indemnities and the Purchaser Indemnities with respect to Claims arising out of or in connection with any breach of or inaccuracy in any
representation, warranty, covenant or agreement contained in this Agreement. 
  

 16 

 Section 5.05 Covenant Not to Compete. Aradigm and its Affiliates agree for a
period of four (4) years after the Closing Date (the “Initial Period”) not to (i) conduct, participate in or sponsor, directly or indirectly, any activities directed toward the research, development of technologies or
products for the delivery of one or more active pharmaceutical ingredients via needle free injection or the manufacture, marketing or distribution of such products (each, a “Competing Activity”) or (ii) appoint, license or
otherwise authorize any Third Party, whether pursuant to such license, appointment, or authorization or otherwise to perform any Competing Activities; provided that during the Initial Period, Purchaser (itself or through one or more Third Parties)
is diligently pursuing the development (including preclinical development) or commercialization of one or more Products. Thereafter during the Royalty Term, Aradigm and its Affiliates agree not to develop or commercialize any product for needle free
injection of any active pharmaceutical ingredient for which Purchaser (itself or through one or more Third Parties) is then actively developing or commercializing a Product incorporating such active pharmaceutical ingredient (or any prodrug,
metabolite, degradant, intermediate, salt form, hydrate, ester, isomer thereof). 
 ARTICLE VI 

MISCELLANEOUS 
 Section 6.01 Press Releases and Public Announcements. No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement prior to the
Closing without the prior written approval of the other Party; provided, however, that (a) either Party may make any public disclosure it believes in good faith is required by applicable law and (b) Aradigm may correspond with Third
Parties in writings in form and substance reasonably satisfactory to Purchaser with respect to obtaining consents from such Third Parties. In furtherance of the foregoing sentence, the Parties agree and acknowledge that either party may issue a
press release regarding this Agreement and the transactions contemplated herein at a time to be mutually agreed after the Closing Date, which press release shall not provide the financial terms of the Agreement. The Parties will provide to each
other a copy of such press release at least five business days prior to its release and such press release shall be subject to written approval of the receiving Party, which approval shall not be unreasonably withheld or delayed. 

Section 6.02 No Third-Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any Person other than
the Parties, and their respective successors and permitted assigns. 
 Section 6.03 Force Majeure. Except with
respect to the payment of money, in the event either Party hereto is prevented from or delayed in the performance of any of its obligations hereunder by reason of acts of God, terrorism, war, invasion, strikes, riots, earthquakes, storms, fires,
energy shortage, acts of government or governmental agencies, or any other cause whatsoever beyond the reasonable control of the Party, the Party so prevented or delayed shall be excused from the performance of any such obligation to the extent and
during the period of such prevention or delay. 
 Section 6.04 Limitation of Liability. NEITHER PARTY SHALL BE
LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

 

 17 

 Section 6.05 Entire Agreement and Modification. This Agreement (including the
exhibits hereto) constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes any prior understandings, agreements, or representations by or among the Parties, written or oral, to the extent they
related in any way to the subject matter hereof. This Agreement may not be amended except by a written agreement executed by all Parties. 
 Section 6.06 Amendment. This Agreement may be amended by Purchaser and Aradigm or any successor thereto by execution by each Party (or their successors) of an instrument in writing.

 Section 6.07 Waivers. The rights and remedies of the Parties to this Agreement are cumulative and not
alternative. Neither the failure nor any delay by any Party in exercising any right, power or privilege under this Agreement or the documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or
partial exercise of such right, power, or privilege will preclude any other or further exercise of such right, power, or privilege or the exercise of any other right, power, or privilege. To the maximum extent permitted by applicable law,
(a) no claim or right arising out of this Agreement or the documents referred to in this Agreement can be discharged by one Party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the other
Party, (b) no waiver that may be given by a Party will be applicable except in the specific instance for which it is given and (c) no notice to or demand on one Party will be deemed to be a waiver of any obligation of such Party or of the
right of the Party giving such notice or demand to take further action without notice or demand as provided in this Agreement or the documents referred to in this Agreement. 
 Section 6.08 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns. This
Agreement shall not be assigned by either Party without the prior written consent of the other Party, except that either Party may assign this Agreement, in whole or in part, to an Affiliate of such Party or to the successor (including the surviving
company in any consolidation, reorganization or merger) or assignee of all or substantially all of its business pertaining hereto. This Agreement will be binding upon any permitted assignee of either Party. No assignment shall have the effect of
relieving any Party to this Agreement of any of its obligations hereunder. 
 Section 6.09 Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. 
 Section 6.10 Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of
this Agreement. Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections and Exhibits to this Agreement and references to this Agreement include all such subparts. Unless context otherwise
clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation”; (b) the word
“day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other
written communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any and all subparts); (e) the word
“or” shall be construed as the inclusive meaning identified with the phrase “and/or”; (f) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or
“approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (g) words of any gender include the other gender;
(h) words using the singular or plural number also include the plural or singular number, respectively; and (i) references to any specific Law or article, section or other division thereof shall be deemed to include the then-current
amendments thereto or any replacement Law thereof. 
  

 18 

 Section 6.11 Notices. All notices and other communications required or permitted
hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by
certified or registered first class mail, postage prepaid, return receipt requested, (b) upon delivery, if delivered by hand, (c) one (1) business day after the business day of deposit with Federal Express or similar overnight
courier, freight prepaid or (d) one business day after the business day of facsimile transmission, if delivered by facsimile transmission with copy by certified or registered first class mail, postage prepaid, return receipt requested and shall
be addressed to the intended recipient as set forth below: 
  

			
	If to Purchaser:
		
	Addressed to:	  	SJ2 Therapeutics, Inc.
		  	3929 Point Eden Way
		  	Hayward, California 94545
		  	Attention: President
		  	Facsimile: (510) 265 0277
		
	With a copy to:	  	Wilson, Sonsini, Goodrich & Rosati
		  	650 Page Mill Rd
		  	Palo Alto, California 94304-1050
		  	Attn: J. Casey McGlynn, Esq.
		  	Facsimile: (650) 493-6811
		
	If to Aradigm:	  	
		
	Addressed to:	  	Aradigm Corporation.
		  	3929 Point Eden Way
		  	Hayward, California 94545
		  	Attention: Chief Financial Officer
		  	Facsimile: (510) 265 0277
		
	With a copy to:	  	Cooley Godward LLP
		  	3175 Hanover Street
		  	Palo Alto, CA 94304-1130
		  	Attn: James Kitch, Esq.
		  	Facsimile: (650) 843-5027

  

 19 

 Any Party may change the address to which notices, requests, demands, claims, and other communications
hereunder are to be delivered by giving the other Party ten days’ advance written notice to the other Party pursuant to the provisions above. 
 Section 6.12 Governing Law. This Agreement shall be governed by and construed in accordance with the domestic laws of the State of California without giving effect to any choice or conflict of
law provision or rule (whether of the State of California or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of California. 

Section 6.13 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. 

Section 6.14 Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship
of any of the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. 

Section 6.15 Attorneys’ Fees. If any legal proceeding or other action relating to this Agreement is brought or otherwise
initiated, the prevailing Party shall be entitled to recover reasonable attorney’s fees, costs and disbursements (in addition to any other relief to which the prevailing Party may be entitled). 

Section 6.16 Further Assurances. The Parties agree (a) to furnish upon request to each other such further information,
(b) to execute and deliver to each other such other documents and (c) to do such other acts and things, all as the other Party may reasonably request for the purpose of carrying out the intent of this Agreement and the documents referred
to in this Agreement. 
 [The remainder of this page left intentionally blank; signature page follows] 

 

 20 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement on of the date first above written.

  

			
	ARADIGM CORPORATION
		
	By:	 	 /s/ Tom Chesterman

	Name:	 	Tom Chesterman
	Title:	 	Senior Vice President and Chief Financial Officer
	
	SJ2 THERAPEUTICS, INC.
		
	By:	 	 /s/ Stephen J. Farr

	Name:	 	Stephen J. Farr
	Title:	 	President

 Schedule 3.06(e) 

Regulatory Documents 
 [***] 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT A 
 Transferred Assets (including Transferred Technology) 
 [***] 

*** Seven (7) pages have been omitted pursuant to a request for confidential treatment. 

 EXHIBIT B 
 Transferred Books and Records 
 [***] 

*** Three hundred twenty four (324) pages have been omitted pursuant to a request for confidential treatment. 

 EXHIBIT C 
 Transferred Contracts 
 [***] 

*** Two (2) pages have been omitted pursuant to a request for confidential treatment. 

 EXHIBIT D 
 Transferred Intellectual Property 
 [***] 

*** Twenty-three (23) pages have been omitted pursuant to a request for confidential treatment. 

  
 EXHIBIT E

 General Assignment and Bill of Sale 

  
 FORM OF BILL OF SALE
AND ASSIGNMENT AGREEMENT 
 This Bill of Sale and Assignment Agreement is made effective as of August 25, 2006, by and
between SJ2 Therapeutics, Inc., a Delaware corporation (“Purchaser”), and Aradigm Corporation, a California corporation (“Aradigm”). All capitalized words and terms used in this Agreement and not defined herein
shall have the respective meanings ascribed to them in the Asset Purchase Agreement dated August 25, 2006 between Aradigm and the Purchaser (the “Asset Purchase Agreement”). 

BACKGROUND 
 WHEREAS, Aradigm and Purchaser have entered into the Asset Purchase Agreement, under which Aradigm has agreed to sell, convey, assign, transfer and deliver the Assigned Assets to Purchaser or its
assigns. 
 AGREEMENT 
  

	1.	Sale. Aradigm does hereby sell, convey, assign, transfer and deliver to Purchaser, and Purchaser does hereby purchase, acquire and accept from Aradigm,
all of Aradigm’s right, title and interest in and to the Assigned Assets, subject to the licensed reserved on behalf of Aradigm pursuant to Section 2.01 of the Asset Purchase Agreement. 

 

	2.	Representations. All representations, warranties, agreements and indemnities of Aradigm with respect to the Assigned Assets set forth in the Asset
Purchase Agreement will continue in effect as provided therein and will not be deemed to be amended, modified, terminated or superseded by or merged with this Bill of Sale and Assignment Agreement. 

 

	3.	Miscellaneous Provisions. 

 3.1. Amendments: Waiver. The terms, provisions and conditions of this Bill of Sale and Assignment Agreement may be amended only by agreement in writing of all parties. No waiver of any
provision nor consent to any exception to the terms of this Bill of Sale and Assignment Agreement or any agreement contemplated hereby will be effective unless in writing and signed by the party to be bound and then only to the specific purpose,
extent and instance so provided. 
 3.2. Further Assurances. Each party will execute and deliver, both before and
after the Closing Date, such further certificates, agreements and other documents and take such other actions as the other party may reasonably request or as may be necessary or appropriate to consummate or implement the Transactions, including to
more effectively transfer the Assigned Assets, or to evidence such events or matters. 
 3.3. Assignment. Neither
this Bill of Sale and Assignment Agreement nor any rights or obligations under it are assignable by one party without the prior written consent of the other party. 

  
 3.4. Descriptive
Headings. The descriptive headings of the sections and subsections of this Bill of Sale and Assignment Agreement are for convenience only and do not constitute a part of this Bill of Sale and Assignment Agreement. 

3.5. Counterparts. This Bill of Sale and Assignment Agreement and any amendment hereto or any other agreement delivered
pursuant hereto may be executed in one or more counterparts and by different parties in separate counterparts. All counterparts will constitute one and the same agreement and will become effective when one or more counterparts have been signed by
each party and delivered to the other party. A facsimile signature page will be deemed an original. 
 3.6. Governing
Laws. This Bill of Sale and Assignment Agreement and the legal relations between the parties will be governed by and construed in accordance with the laws of the State of California applicable to contracts made and performed in such State
and without regard to conflicts of law doctrines unless certain matters are preempted by federal law. 
 3.7.
Waiver. No failure on the part of any party to exercise or delay in exercising any right hereunder will be deemed a waiver thereof, nor will any single or partial exercise preclude any further or other exercise of such or any other right.

 3.8. Representation By Counsel: Interpretation. The parties each acknowledge that each has been represented by
counsel in connection with this Bill of Sale and Assignment Agreement and the transactions contemplated by the Asset Purchase Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities
in this Bill of Sale and Assignment Agreement against the party that drafted it has no application and is expressly waived. The provisions of this Agreement will be interpreted in a reasonable manner to effect the intent of the parties hereto.

 3.9. Severability. If any provision of this Bill of Sale and Assignment Agreement is held to be unenforceable
for any reason, it will be adjusted rather than voided, if possible, to achieve the intent of the parties. All other provisions of this Bill of Sale and Assignment Agreement will be deemed valid and enforceable to the extent possible. 

[signature page to follow] 

  
 2 

  
 IN WITNESS
WHEREOF, Aradigm and Purchaser have caused this Bill of Sale and Assignment Agreement to be duly executed as of the day and year first above written. 
  

									
	PURCHASER:	 		 	ARADIGM:
			
	SJ2 THERAPEUTICS, INC.	 		 	ARADIGM CORPORATION
					
	By:	 	 /s/
	 		 	By:	 	 /s/

					
	Name:	 	 Stephen J. Farr
	 		 	Name:	 	 T.C. Chesterman

					
	Title:	 	 President
	 		 	Title:	 	 SVP & CFO

  
 EXHIBIT F

 Assumed Liabilities 
 1. All obligations under Assumed Contracts, other than obligations due and owing as of the date of the Agreement to Third Parties that are parties to such Assumed Contracts. 

2. Liabilities (other than Excluded Liabilities) incurred in the use of the Assigned Assets following the Closing Date. 

3. See attached list for additional items. 
 [***] 
 *** Twenty-two (22) pages have been omitted pursuant to a request for
confidential treatment. 

  
 EXHIBIT G

 Transfer Plan 
 [***] 
 *** Six (6) pages have been omitted pursuant to a request for confidential
treatment. 

  
 EXHIBIT H

 Transitional Services Agreement 

  

[ARADIGM LETTERHEAD] 
 August 25, 2006 
 SJ2 Therapeutics, Inc. 

 

	Re:	Transition Services 

 Ladies and
Gentlemen: 
 SJ2 Therapeutics, Inc. (“SJ2”) and Aradigm Corporation (“Aradigm”) are entering into an Asset
Purchase Agreement (the “APA”) dated as of the date of this letter (the “Effective Date”), which, among other things, provides for the sale to SJ2 of certain Aradigm assets related to the development, manufacture, and
commercialization of Aradigm’s Intraject Delivery System. 
 1. Services. On the terms and subject to the conditions
contained herein, Aradigm shall provide, or shall cause third parties designated or hired by it (such designated third parties, together with Aradigm, the “Service Providers”) to provide to SJ2 the following services (collectively, the
“Services”) for the time period through December 31, 2006 (“Expiration Date”): 
  

	 	(a)	General information technology services and support (e.g., e-mail access, computer equipment and software support, network access and support to SJ2’s server only,
and other general computer technologies support) within Aradigm’s current systems and procedures until SJ2 vacates Aradigm’s facilities or the Expiration date, which ever is earlier, 

 

	 	(b)	Telephone and fax services and support, 

  

	 	(c)	Aradigm will provide SJ2 with document control support for the activities documented in Aradigm’s current document control processes, using Aradigm’s Document
Control System (DCS) database. Aradigm has assumed that SJ2 will purchase the DCS on or shortly after the Effective Date. It is Aradigm’s intention to hire a temporary senior level Document Control Specialist, on or shortly after the Effective
Date, who will be fully funded by SJ2, to allow Aradigm’s current document control personnel to provide document control support to SJ2 consistent with Aradigm’s current Document Control processes. If Aradigm is unable to hire a temporary
senior level Document Control Specialist, or should the temporary employee hired leave Aradigm for any reason, Aradigm will not be able to provide the services described in this section 1(c). 

 

	 	(d)	Human resources services and support for Aradigm consultants transferring to SJ2, 

 

	 	(e)	Payment for individual Aradigm consultants transferring to SJ2, 

  
 1 

  

	 	(f)	Technical consulting as available and approved in writing by both parties, 

 

	 	(g)	Office facilities, furnishings, and services (e.g., utilities, maintenance, mail, etc.), and 

 

	 	(h)	Such other services as Aradigm and SJ2 may agree to as set forth in paragraph 4. 

 2. Current Invoices. Exhibit A to this letter contains an invoice for transitional services provided by Aradigm to SJ2 through the months of July and August 2006. The parties acknowledge that a
secondary invoice will be provided to SJ2 relating to transitional service provided at the time of closing Aradigm’s August accounting records. As Aradigm’s August accounting records have not been closed as of the Effective Date,

 3. Term of Agreement. Except for the services performed prior to the Effective Date as referenced in paragraph 2, all
services to be provided under this Agreement shall begin as of the Effective Date and shall terminate on the Expiration Date. Aradigm and SJ2 will negotiate in good faith if SJ2 needs to extend the term of this letter and/or any provision of any
Service beyond the Expiration Date (and the parties hereby acknowledge that the negotiation of any such extension may involve a renegotiation of the charges with respect to any such Services). This letter may be extended upon the mutual agreement of
the parties hereto in writing, either in whole or with respect to one or more of the Services; provided that, such extension shall only apply to the specific Services for which this letter was extended. Services shall be provided up to and including
the applicable Expiration Date, subject to earlier termination as provided in this letter. 
 4. Additional Services.
From time to time after the Effective Date, Aradigm and SJ2 may identify and mutually agree upon additional services to be provided to SJ2 in accordance with the terms of this letter (the “Additional Services”). At such times, the parties
shall execute an addendum to this Agreement setting forth a description of any Additional Service, the time period during which such Additional Service will be provided, the charge for such Additional Service and any other terms applicable. Aradigm
and SJ2 acknowledge that charges for Additional Services will include a profit margin consistent with industry standards for the provision of similar services. Additional Services may include, but shall not be limited to, regulatory consulting for
the Intraject Sumatriptan NDA, clinical training of the CRO selected to conduct the Intraject bioequivalence study, submission of the Intraject Sumatriptan IND on behalf of SJ2 and assistance with R&D efforts. 

5. Provision of Services. Aradigm will use commercially reasonable efforts to ensure that employees and Service Providers are
available to perform its obligations hereunder. Aradigm shall provide the Services in accordance with the policies, procedures and practices in effect as of immediately prior to the Effective Date. Aradigm and SJ2 will use their commercially
reasonable efforts to promote a smooth and efficient transition of operations. 

  
 2 

  
 6. No
Warranties. ARADIGM WILL USE COMMERCIALLY REASONABLE EFFORTS TO CAUSE THE SERVICES TO BE PERFORMED IN A PROFESSIONAL AND COMPETENT MANNER; HOWEVER, ARADIGM DOES NOT MAKE ANY WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO
THE IMPLIED WARRANTIES OF MERCHANTABILITY, BUSINESS CONTINUITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE SERVICES, MATERIALS OR OTHER DELIVERABLES PROVIDED, OR CAUSED TO BE PROVIDED, BY IT UNDER THIS LETTER. 

7. Transition to SJ2 Systems and Personnel. During the term of this letter, Aradigm will use reasonable efforts to provide to SJ2,
at SJ2’s expense, consultation, assistance and information as reasonably requested by SJ2, and will otherwise perform the Services, so as to effect a smooth transition from SJ2’s utilization of Aradigm’s systems and personnel to
SJ2’s utilization of its own systems and personnel in connection with the development of the Intraject Delivery System prior to the termination or expiration of this letter. 

8. Payments. SJ2 shall pay Aradigm on a monthly basis for documented actual charges for the performance of the Services. Aradigm
will invoice SJ2 for its representatives’ activities using an hourly rate based on salary, benefits and overhead of the Aradigm representatives performing the Services. Aradigm will not apply a profit to its representatives’ hourly rates
through the Expiration Date. 
 9. Discontinuation of Services. If SJ2 chooses to discontinue any Service prior to the
Expiration Date, SJ2 shall give at least 30 days prior written notice, of its intent to terminate this letter as to that particular Service, which termination as to that particular service shall be effective on the last day of the month on which the
30 days prior written notice lapses. SJ2 will pay Aradigm hereto the fees and costs of any terminated Service up until the effective date of termination of such Service. 
 10. Termination. Notwithstanding anything to the contrary contained in this letter, this letter may be terminated, in whole or in part, at any time: (a) by the mutual consent of SJ2 and
Aradigm; or (b) by either SJ2 or Aradigm in the event of any material breach or default by the other party of any of its obligations under this letter and the failure of such defaulting party to cure, or to take substantial steps towards the
curing of, such breach or default within 14 days after receipt of written notice from the non-defaulting party requesting such breach or default to be cured. 
 11. No Implied Responsibilities or Obligations. NO PARTY HERETO ASSUMES ANY RESPONSIBILITY OR OBLIGATIONS WHATSOEVER, OTHER THAN THE RESPONSIBILITIES AND OBLIGATIONS EXPRESSLY SET FORTH IN THIS
LETTER OR A SEPARATE WRITTEN AGREEMENT BETWEEN THE PARTIES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS LETTER TO THE CONTRARY, IN NO EVENT SHALL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR ANY LOST PROFITS, LOSS OF DATA, LOSS OF USE, BUSINESS
INTERRUPTION OR OTHER SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES. 

  
 3 

  
 12. Independent
Contractors. The relationship between SJ2 and Aradigm established under this letter is that of independent contractors and no party shall be deemed an employee, agent, partner, or joint venturer of or with the other. Each Service Provider will
be solely responsible for any employment-related taxes, insurance premiums or other employment benefits respecting its personnel’s performance of any Services. SJ2 agrees to grant to any applicable Service Provider’s personnel reasonable
access to sites, systems and information as necessary for the Service Provider to perform its obligations under this letter. The personnel of SJ2 and Aradigm shall agree to obey any and all security regulations and other published policies of the
other party relevant to the provision or receipt of any Services. 
 13. Confidentiality. Any information from time to
time communicated or delivered by SJ2 or Aradigm to the other party, including without limitation trade secrets, business methods, and cost, supplier, manufacturing and customer information, shall be treated by SJ2 and Aradigm, respectively, as
confidential information of the other party, and shall not be disclosed or revealed to any third party whatsoever or used in any manner except as expressly provided for in this letter; provided, however that such confidential information shall not
be subject to the restrictions and prohibitions set forth in this paragraph 13 to the extent that such confidential information: (a) is available to the public in public literature or otherwise, or after disclosure by one party to the other
becomes public knowledge through no default of the party receiving such confidential information; or (b) was known to the party (as demonstrated by the written records of such party) receiving such confidential information with no obligation to
maintain confidentiality prior to the receipt of such confidential information by such party, whether received before or after the date of this letter; or (c) is obtained by the party receiving such confidential information from a third party
not subject to a requirement of confidentiality with respect to such confidential information. For the avoidance of doubt, information will not be considered to be available to the public, in the public literature, or in the prior possession of the
receiving party merely because individual elements thereof are available to the public, in the public literature, or in the prior possession of the receiving party, unless the combination of such elements is available to the public, in the public
literature, or in the prior possession of the receiving party. SJ2 and Aradigm shall take all such precautions as it normally takes with its own confidential information to prevent any improper disclosure of such confidential information to any
third party; provided that, such confidential information may be disclosed: (x) pursuant to any order of a court or government entity having jurisdiction and power to order such information to be released or made public; (y) within
the limits required to obtain any authorization from any governmental or regulatory agency; or (z) with the prior written consent of the other party, which shall not be unreasonably withheld, as may otherwise be required in connection with the
purposes of this letter. 
 14. Access to Aradigm Computer Systems. If SJ2 is given access to any computer equipment,
computer, software, network, electronic files, or electronic data storage system owned or controlled by Aradigm (“Aradigm Computer Systems”), then 

  
 4 

 
SJ2 shall limit access and use of such Aradigm Computer Systems solely to receive Services under this letter and shall not access, attempt to access or use any Aradigm Computer Systems, other
than those specifically required to receive the Services. All user identification numbers and passwords disclosed to SJ2 and any of Aradigm’s confidential information obtained by SJ2 as a result of its access to and use of any such Aradigm
Computer Systems shall be deemed to be, and shall be treated as, Aradigm’s confidential information under applicable provisions of this letter. SJ2 agrees to cooperate with Aradigm in the investigation of any apparent unauthorized access by SJ2
or its representatives to any Aradigm Computer Systems, or any apparent unauthorized release of Aradigm’s confidential information by the employees, contractors or advisers of SJ2. 

15. Indemnification. SJ2 indemnifies Aradigm and its affiliates against, and agrees to hold each of them harmless from, any and
all damage, loss, liability and expense (including reasonable expenses of investigation and reasonable attorneys’ fees and any incidental, indirect or consequential damages, losses, liabilities or expenses) (“Damages”) incurred or
suffered by Aradigm or any of its affiliates (other than Damages incurred or suffered by Aradigm or any of its affiliates arising from any claims made by employees of Aradigm) that arise from any third-party claim for personal injury or damage to
property based upon the performance of the Services by any of Aradigm’s employees, except to the extent such third-party claim arises out of such employee’s negligence, willful misconduct or breach of obligations under this letter. Aradigm
indemnifies SJ2 and its affiliates against, and agrees to hold each of them harmless from, any and all Damages incurred or suffered by SJ2 or any of its affiliates (other than Damages incurred or suffered by SJ2 or any of its affiliates arising from
any claims made by employees of SJ2) that arise from any third-party claim for personal injury or damage to property based upon actions by any of SJ2’s employees under the terms of this letter, except to the extent such third-party claim arises
out of such employee’s negligence, willful misconduct or breach of obligations under this letter. 
 16. Existing
Ownership Rights Unaffected. Neither SJ2 nor Aradigm will gain, by virtue of this letter, any rights or ownership of copyrights, patents, know-how, trade secrets, trademarks or any other intellectual property rights owned by the other party.

 17. Dispute Resolution. All disputes arising out of this letter shall be settled as far as possible by negotiations
between SJ2 and Aradigm. If SJ2 and Aradigm cannot agree on an amicable settlement within 30 days from written submission of the matter by one party to the other, the matter shall be shall be settled by binding arbitration in the County of Hayward
in the State of California in accordance with the Commercial Arbitration Rules then in effect of JAMS/Endispute. Arbitration will be conducted by one arbitrator, mutually selected by SJ2 and Aradigm. If Aradigm and SJ2 fail to mutually select an
arbitrator within 15 days following the submission of the matter to JAMS/Endispute, then arbitration will be conducted by three arbitrators: one selected by Aradigm; one selected by SJ2; and the third selected by the first two arbitrators. If SJ2 or
Aradigm fails to select an arbitrator within ten days following the expiration of the initial 15 day period, then the other shall be entitled to select the second arbitrator. SJ2 and 

  
 5 

 
Aradigm agree to use all reasonable efforts to cause the arbitration hearing to be conducted within 75 days after the appointment of the mutually selected arbitrator or the last of the three
arbitrators, as the case may be, and to use all reasonable efforts to cause the decision of the arbitrators to be furnished within 95 days after the appointment of the mutually selected arbitrator or the last of the three arbitrators, as the case
may be. SJ2 and Aradigm further agree that discovery shall be completed at least 10 days prior to the date of the arbitration hearing. The final decision of the arbitrators shall be furnished to SJ2 and Aradigm in writing and shall constitute a
conclusive determination of the issues in question, binding upon SJ2 and Aradigm and shall not be contested by any of them. The non-prevailing party in any arbitration shall pay the reasonable expenses (including attorneys’ fees) of the
prevailing party and the fees and expenses associated with the arbitration (including the arbitrators’ fees and expenses). For purposes of this paragraph 17, the non-prevailing party shall be determined solely by the arbitrators. 

18. No Third Party Beneficiaries. This letter shall not confer any rights or remedies upon any person or entity other than SJ2 or
Aradigm and their respective successors and permitted assigns. 
 19. Counterparts and Facsimile Signature. This letter
may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. This letter may be executed by facsimile signature. 

20. Notices. All notices and other communications under this letter will be in writing and deemed to have been duly given if given
in accordance with Section 6.11 of the APA. 
 21. Successors and Assigns. The provisions of this letter shall be
binding upon and inure to the benefit of SJ2 and Aradigm and their respective successors and assigns; provided, however, that except as expressly provided in this letter, no party may assign, delegate or otherwise transfer any of its rights or
obligations under this letter without the consent of each other party. 
 [The remainder of this page is left intentionally
blank; signature page follows] 

  
 6 

  
 If you are in agreement with the terms
of this letter, please execute this letter where indicated below and return a copy of the signed letter to Aradigm. 
  

			
	ARADIGM CORPORATION
		
	By:	 	 /s/

	Name:	 	T.C. Chesterman
	Title:	 	SVP & CEO

  

			
	ACCEPTED AND AGREED TO:
	
	SJ2 THERAPEUTICS, INC.
		
	By:	 	 /s/

	Name:	 	Stephen J. Farr
	Title:	 	President

  
 7 

  
 EXHIBIT I

 Intraject Delivery System 

  
 EXHIBIT I

 Technical Description of the Intraject System 
 Intraject is a pre-filled, disposable, sterile delivery device, which is designed to deliver up to 0.5mL into the subcutaneous tissue. Intraject demonstrably delivers the injectate into the subcutaneous
tissue similar to needle injection. Intraject works by using a small canister of nitrogen gas, under pressure, to accelerate a metal rod towards a modified-PTFE piston. This piston is in contact with the liquid drug formulation, and the impact of
the metal rod generates pressure in the drug formulation. The other end of the drug container has a small orifice, which is held in contact with the skin. The initial high pressure is sufficient to cause the liquid to be ejected through the orifice
and to pierce the skin. The bulk of the liquid is subsequently delivered at a lower pressure into the subcutaneous tissue where it is available for systemic absorption. 

 

 

 The Intraject System consists of the following components: 
 1. The Capsule sub-assembly, which stores the pre-filled sterile injection solution. 
 2.
The Actuator sub-assembly, which is the mechanism that expels the injection solution when actuated. 
 3. The Setting Mechanism,
which provides a convenient means for the user to set the actuator triggering mechanism 
 Appropriate materials that are compatible with the
formulation, device capabilities and sterilization methods have been chosen as a result of the development program for the Intraject System. 

  
 Components of the
Capsule sub-assembly 
 The primary packaging component of the Intraject® sumatriptan drug product is the Capsule sub-assembly. The
formulation contact materials of the capsule sub-assembly are typical of those used in the manufacture of pharmaceutical products. 
 The
Capsule sub-assembly has five components (Figure P.2-1). 
 The material, function and design rationale for use of each primary packaging
component is described below: 
  

	 	1.	Glass capsule: The glass capsule material is a USP Type 1 borosilicate glass capsule, strengthened via an ion exchange surface treatment process, which stores the
injection solution. The material was chosen for its known compatibility with drug formulations, for its clear appearance which allows observation of the formulation solution, and because it is resistant to chemical degradation, impermeable to
solvent transport, and easy to sterilize. This material is widely used within the pharmaceutical industry as a formulation contact material. 

  

	 	2.	Piston: Modified PTFE piston ([***]): The piston seals one end of the capsule and expels the injection solution when the device is actuated. The material was chosen to
ensure appropriate amounts of friction between the piston and capsule during actuation, to provide sufficient transfer of energy between the ram and formulation solution during actuation, to ensure limited solvent transport out of the capsule, to
ensure acceptable seal integrity across an appropriate temperature range, and to be easy to sterilize. The material was also chosen for its non-reactivity and compatibility with drug formulations. This material is used in medical implants and
pharmaceutical processing. 

  

	 	3.	Stopper: Chlorobutyl rubber stopper, which seals the other end of the capsule. The material was chosen because of its known compatibility with drug formulations, its
elasticity which provides acceptable seal integrity across an appropriate temperature range, because it has low solvent transport properties, and is easy to sterilize. It is one of the most widely used elastomeric container-closure materials in the
pharmaceutical industry. 

  

	 	4.	Interface seal: Chlorobutyl rubber interface seal that allows sterile filling under vacuum. The material is the same as that used for the stopper, and was chosen for
the same reasons. 

  

	 	5.	Capsule sleeve: Polyurethane capsule sleeve, which protects the capsule and couples the capsule sub-assembly to the actuator. The material was chosen to be
sterilizable, to provide visibility into the glass capsule, and to enable removal of the “snap-off’ end of the capsule sleeve by the user with an appropriate force. This material is medical-grade, and has very limited exposure to the
formulation solution. 

 Figure 2-1: Schematic of Capsule Sub-Assembly Components 

 
 Components of Actuator Sub-Assembly 

As shown in Figure P.2-2, the Actuator sub-assembly has twelve functional components. The actuator components have no drug formulation contact.

  

					
		
	 	I.	  	  	An actuator sleeve that restrains the latch until the device is actuated.
		
	 	II.	  	  	A chamber that stores the pressurized gas for expelling the injection solution.
		
	 	III.	  	  	 Two-O-rings thatseal between the ram and the chamber to prevent gas loss.

		
	 	IV.	  	  	A ram that drives the piston down the capsule when the device is actuated, thus expelling the injection solution through the drilled orifice.
		
	 	V.	  	  	A latch, which restrains the ram from moving until the time of injection.
		
	 	VI.	  	  	A coupling to join the actuator to the capsule sub-assembly.
		
	 	VII.	  	  	An outer ring to strengthen the actuator sleeve where the latch pushes against it.
		
	 	VIII.	  	  	A coupling clip to join the chamber to the coupling.
		
	 	IX.	  	  	A shock absorber that controls the rise of pressure in the fluid and prevents shock waves.

 
  

			
	1 ***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

  

	 	10.	[***]. 

  

	 	11.	 [***].2 

  

	 	12.	[***]. 

  

	 	13.	[***]. 

  

	 	14.	[***]. 

  

	 	15.	[***]. 

 Figure P.2-2: Schematic of Actuator
Sub-Assembly Components 
 [***] 

Table P.2-1 provides information on the materials used to manufacture the individual actuator components. 

[***] 
 Components of Setting
Mechanism 
 The presentation of the Intraject System consists of a Setting Mechanism, which encases the filled and assembled Actuator and
Capsule sub-assemblies for the convenience of the user. The Setting Mechanism does not alter the drug delivery from the device and the components have no drug formulation contact. 
 The Setting Mechanism has been developed as a result of risk analysis and human factors evaluations and addresses issues identified during these assessments. The specific patient-device factors the
Setting Mechanism addresses are: 
  

	 	•	 	 It provides a convenient means for the user to set the actuator triggering mechanism. 

 

	 	•	 	 It improves the intuitiveness of use of the device by providing visual cues to the preparation steps and also forces the user to prepare the Intraject
System for injection in the correct order. 

  

	 	•	 	 It improves the ergonomics of the device by aiding removal of the capsule snap-off tip and provides the user with a grip to hold the device during
snap-off, priming and injection. 

  

			
	2 ***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

  
 The Setting Mechanism consists of
three functional parts as shown in Figure P.2-3: 
 Figure P.2-3: Setting Mechanism 

 

 

  

	 	1.	A snap-off cap, made up of two identical halves, which encloses the snap-off portion of the capsule sleeve. It provides an extended lever-arm to assist the user in
breaking the snap-off while also releasing the setting lever (thereby forcing the correct sequence during use). 

  

	 	2.	A setting lever that can only be operated when the snap-off cap is removed. When rotated and placed into the groove in the cover, the setting lever both sets the
actuator triggering mechanism whilst also removing a block from between the actuator and capsule sub-assemblies (to facilitate subsequent actuation, only when pressed against the skin). 

 

	 	3.	A grip, made up of the collar and cover components. The grip supports the actuator sub-assembly and the lever and is held by the patient during use. A pin on the collar
component drives into and sets the actuator triggering mechanism as the user rotates the lever into the cover. At the same time, a block on the cover component is removed from between the two Intraject sub-assemblies to facilitate subsequent
injection when pressed against the skin by the user. 

 Table P.2-8 provides information on the materials used to
manufacture the setting mechanism. 
 Table P.2-8: Components of the Setting Mechanism 

[***].3
 
 Table P.2-9 provides information on the actuator and setting
mechanism materials, and rationale for their selection. 
  

			
	3 ***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

  
 [***].4 
 Figure P.2-4 shows the three basic steps to using the Intraject® System with Setting Mechanism. 
 Figure P.2-4: Three Basic Steps for Using the Intraject System 

 

 

  

			
	4 ***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

  
 EXHIBIT J

 Nontransferable Assets 
 None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]